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Abstract 
Myelination plays a key role in both the developing CNS and repair from neurodegenerative 
diseases such as multiple sclerosis (MS). Previous work has suggested a role for the 
amphoterin-induced gene and open reading frame (AMIGO) family of proteins, like other 
members of the leucine-rich repeat immunoglobulin domain (LRRIG) superfamily, in repair 
within the CNS. This thesis proposes a novel role for the AMIGOs in both the developmental 
and repair processes of myelination. The immunofluorescent staining results presented here 
show that the AMIGOs are expressed in the developing mouse brain in a similar, progressive 
pattern to that of myelination up to at least day 28. These results also show that the AMIGO 
proteins are expressed by oligodendrocyte precursor cells (OPCs), mature oligodendrocytes 
and astrocytes in the spinal cord during experimental autoimmune encephalomyelitis (EAE), 
an animal model of MS. These cells play a pivotal role in myelination, as either myelinating 
cells or regulators. The knockdown of AMIGO3, however, was shown not to affect OPC 
differentiation. These combined results suggest a role of this family of proteins as potential 
positive regulators of both myelination during development and remyelination post-disease. 
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1. Introduction 
1.1 Myelination and oligodendrocytes 
Myelin is an electrically insulating material that coats the axon of neurons to form the myelin 
sheath. It is synthesised by mature oligodendrocytes, a type of glial cell, shortly after birth in 
mammals. Oligodendrocytes are formed in the neuroepithelium of the spinal cord and 
subsequently migrate within the CNS. Oligodendrocytes differentiate from oligodendrocyte 
progenitor cells (OPCs) within CNS tissues. OPCs constitute 8-9% of white matter of rat 
brain (Dawson et al., 2003). Each oligodendrocyte extends processes, which make contacts 
with 20-40 axonal segments via surface receptors. Signals from these receptors trigger 
myelin to form as an extension of the oligodendrocyte cell membrane, which wraps 
repeatedly around axons to form the sheath as seen in figure 1 (Hildebrand et al., 1993; 
Umemori et al., 1999). The gaps between these structures form the nodes of Ranvier. The 
myelin sheath gives axons a white appearance, hence “white matter”, and comprises the 
most abundant membrane structure of the vertebrate nervous system.  
The primary function of myelin is to allow high-speed nerve propagation with a minimum 
amount of energy expenditure. This is achieved by its dielectric properties primarily due to its 
high protein content (around 80% dry weight). Around 30% of this protein is myelin basic 
protein (MBP), a functionally important structural protein (Umemori et al., 1999), while other 
proteins include the myelin oligodendrocyte glycoprotein (MOG) and proteolipid protein (PLP).  
 2 
The process of myelination starts within the embryo and relatively late on in the development 
of the CNS, but can continue for a much longer time postnatally depending on the animal. 
Developmental myelination occurs in humans up until adolescence or beyond, particularly in 
regions such as the corpus callosum and corticospinal tract (Paus et al., 1999). Infant brain 
myelination is seen to occur asymmetrically; with myelination of the left-brain occurring more 
rapidly than that of the right, although the opposite is observed in the cerebellum (Deoni et al., 
2011).  
Figure 1 Ensheathment of an axon by oligodendrocytes The cell membrane of an 
oligodendrocyte extends and enfolds the axon with a distinct protein and lipid composition 
to form the myelin sheath. Microtubules, stabilised by MBP, give structure and allow 
transport of RNA, mRNA and ribosomes transport to distal sites of protein synthesis. 
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Without myelin, the conduction of the action potential can be severely impaired, resulting in 
paralysis and numbness such as that observed in diseases like multiple sclerosis (MS). The 
loss of the trophic support provided by the oligodendrocytes further predisposes axons to 
more severe injury (Trapp et al., 1998). 
1.2 Demyelination and oligodendrocyte destruction in MS 
MS is a sporadic, acquired, inflammatory disorder of the human brain and spinal cord. MS 
affects upwards of 2.5 million people worldwide, with the usual onset of symptoms in a 
person’s late 20’s to early 30’s (Ransohoff, 2012). Disease progression is normally 
characterised by episodes of sporadic neurological deficits and periods of substantial 
remission; known as the relapsing-remitting stage, illustrated in figure 2. Between 8-20 years 
post onset, sufferers often enter the secondary progressive stage; characterised by severe, 
irreversible neurological disability (Trapp et al., 1999). These neurological deficits are 
heterogeneous and may involve any part of the central nervous system (CNS), however, half 
of all patients require aid while walking 15 years after the onset (Weinshenker et al., 1989). 
On average, life expectancy of MS sufferers is reduced by around ten years due to the 
chronic debilitating nature of the disease, defining MS as a leading cause of non-traumatic 
disability among young adults (Brønnum-Hansen, 2004; Noseworthy et al., 2000). 
The primary cause of neurological deficits in MS sufferers is demyelination and destruction of 
oligodendrocytes, neurons and axons. This is caused by the invasion of the CNS by immune 
cells, which target the myelin sheath. MS has therefore been classically defined as an 
autoimmune disease, however the evidence for this is weak and circumstantial (Wootla et al., 
2012). MS is now increasingly being recognised as a neurodegenerative disease triggered 
by an inflammatory attack of the CNS. There is no known definitive cause for MS; as such it 
is simply classified as a progressive, episodic, demyelinating disorder of the CNS. 
Entry into the secondary progressive stage of MS is due to accumulation of axon 
degeneration. This may be myelin-dependent through altered ion channels, or myelin-
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independent through perturbed mitochondrial function, reduced ATP/ADP balance and 
subsequent reduced axonal transport and axonal swellings (Nave, 2010). This irreversible 
degeneration correlates with permanent neurological disability.  
Current MS treatments are largely immunosuppressive, with the use of drugs such as 
methylprednisolone and interferon alpha, with no oligodendrocyte-based treatment. These 
treatments passively treat oligodendrocytes and myelin destruction by modulating the 
inflammatory response. Although they appear to reduce the severity of symptoms and the 
frequency of relapse, they do not treat the pathological progression of the disease. The 
protection of oligodendrocytes and myelin or reversal of demyelination and axonal loss, and 
therefore progression from relapsing-remitting to secondary progressive MS, may therefore 
be of clinical significance. 
An increase in the migration of a heterogeneous population of immune cells and chemicals 
across the blood-brain barrier is thought to be the primary trigger of MS. Regulatory defects 
within immune cells result in an immune response occurring within the CNS, primarily against 
myelin and oligodendrocytes. This inflammation is the first of four pathological features of the 
disease; followed by demyelination, axonal damage and reactive gliosis (Brück, 2005).  
Once an immune response has been set up within the CNS, there are four main mechanisms, 
both biochemical and cellular, through which myelin and oligodendrocytes may be destroyed 
(Brück, 2005). B cell antibody-mediated autoimmune demyelination is the most frequently 
Figure 2 Relapse-remitting MS disease progression Unpredictable attacks of varying 
severity, which may or may not leave permanent deficits in ability followed by periods of 
remission. 
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observed pathology, occurring in over half of MS sufferers (Brück, 2005). The release of 
antibodies by B cells can result in the activation of complement and macrophages, leading to 
opsonization and phagocytosis. Another major pathology is that of T cell-mediated 
autoimmune demyelination; either the direct binding of T cells to epitopes on the myelin 
sheath, or the release of cytotoxic cytokines and soluble toxic mediators. Distal 
oligodendrogliopathy and initiation of the apoptotic cascade may also occur after non-lethal 
damage to oligodendrocytes as well as primary oligodendrocyte degeneration triggered by 
viruses and environmental toxins if the cells are weak after myelin damage. 
 The focal tissue damage forms multiple characteristic sclerotic plaques within the white 
matter of the CNS (Brück, 2005). These hallmarks represent the end stage of the 
degenerative process, from inflammation to neuronal and axonal degeneration. 
1.3 Remyelination 
The characteristics of relapsing-remitting MS are the degeneration of myelin, 
oligodendrocytes and axons and subsequent repair of this damage to varying degrees. 
During this process the inflammatory site changes from destructive to remyelinating despite 
the presence of immune cells (Ozawa et al., 1994). Although most active during the acute 
stages of the disease this process also occurs in the progressive phase, around 20% of 
lesions are fully repaired to form shadow plaques, defined as focal areas with reduced myelin 
density (Compston and Coles, 2008; Barkhof et al., 2003, Patrikios et al., 2006) 
The recapitulating hypothesis suggests that remyelination occurs via the same mechanism 
as developmental myelination (Fancy et al., 2011). Importantly, it has also been suggested 
that the process of remyelination as a repair mechanism may differ from that of 
developmental myelination (Arnett et al., 2004). Whether the recapitulating hypothesis is 
correct or not, certain similarities are at least agreed on between the two processes. As with 
developmental myelination, oligodendrocytes play a fundamental role in the endogenous 
repair mechanism. Oligodendrocytes exhibiting an immature phenotype have been 
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documented in recently formed sclerotic plaques, suggesting that the oligodendrocytes 
involved in remyelination are newly differentiated (Wolswijk, 1998a). There is also a positive 
correlation between the number of oligodendrocytes in freshly formed lesions and the length 
of survival (Prineas et al., 1993). The presence of OPCs is therefore presumed to provide 
new oligodendrocytes that can remyelinate the naked axons within the lesion (Compston and 
Coles, 2008).  
The extent to which plaques are remyelinated is highly heterogeneous, both between 
patients and between plaques found in the same patient (Patani et al., 2007). However, over 
time remyelination ceases to occur. The cessation is not due to a lack of OPCs as these cell 
populations have been found (Wolswijk et al., 1998b) suggesting impairment of the 
differentiation and proliferation processes of the OPCs. The reason for this effectively 
exhausted repair may be due to an absence of a growth factor, the presence of an inhibitory 
molecule or the build up of scar tissue (Woswijk, 1998b). If the cause can be elucidated, it 
may prove an important therapeutic target. 
1.4 Experimental autoimmune encephalomyelitis (EAE) 
EAE is an inflammatory demyelinating disease of the CNS (secondary to severe 
inflammation), used as an animal model of brain inflammation. The disease is induced by 
systemic injection of CNS-antigens and adjuvant, such as those to MBP, in order to induce 
an immune response specific to the CNS. It is the most widely used model to study MS as 
they share both clinical and pathological features (Lassmann, 1983). The form most similar 
to the relapsing-remitting stage of MS is seen in the chronic relapsing form (CREAE) 
exhibited by the Biozzi ABH mouse (Biozzi et al., 1972). 
 7 
However, as with any animal model, 
there are limitations. For example it 
has been suggested that a different 
subtype of T-lymphocytes drive the 
disruption of the blood-brain barrier 
via secretion of a different array of 
interleukins than during MS 
(Compston and Coles, 2008). The 
use of potent adjuvant to initiate the 
disorder may bypass some 
fundamental stages in MS initiation 
and progression (Caprariello et al., 
2011). However, it is still 
considered a highly similar and 
relevant model, particularly for the 
study of remyelination. 
 
1.5 The LRRIG domain and LINGO1 
The leucine-rich repeat (LRR) and immunoglobulin (Ig) domains are two discrete motifs, 
which differ in function and are found in 3% and 0.9% of all proteins in the human proteome, 
respectively (Pruess et al., 2003). The LRR domain was first found in the leucine-rich !2-
glycoprotein and is involved in protein-protein recognition processes. It is a sequence of 11 
conserved aliphatic amino acids, including leucine. The Ig domain consists of two anti-
parallel "-sheets with a Greek key topology. Currently, there are 36 known proteins 
containing at least one copy of each of these motifs, known as LRRIG proteins, which can be 
further classified into 13 subgroups (Homma et al., 2009). Around two thirds of these LRRIG 
Figure 3 Domain organisation of LRRIG proteins A 
schematic representation of three LRRIG proteins: 
AMIGO1, LINGO1 and LRIG1. Each share very similar 
structures, consisting of a transmembrane segment, at 
least one Ig-like domain, varying numbers of LRRs and 
a signal peptide. 
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proteins are expressed within the central nervous system, including the LRR and Ig domain-
containing, Nogo-receptor interacting protein 1 (LINGO1). 
LINGO1, a member of the LINGO subgroup, is a highly conserved membrane-bound protein 
of 614 amino acids. As seen in figure 3, it consists of 12 LRR motifs, a single Ig-like domain, 
a transmembrane domain and a short cytoplasmic tail (Mi et al., 2004). LINGO1 is a co-
receptor of the neuronal Nogo-66 receptor (NgR)/p75 neurotrophin signaling complex (figure 
4). Components of myelin, such as MAG and Nogo, stimulate this receptor complex, in turn 
Figure 4 The LINGO1/NgR/p75 receptor complex The inhibitors Nogo-A and MAG 
intercellularly bind to the LINGO1/NgR/p75 neurotrophin signaling complex. On ligand 
binding, the RhoGDI-RhoA complex binds to p75, causing a strong inhibition of RhoGDI. 
This permits a guanine exchange factor (GEF) to perform GDP-GTP exchange leading to 
active stabilisation and subsequent inhibition of neurite outgrowth. 
 9 
activating RhoA and signaling the collapse of neural growth cones (Ahmed et al., 2006). 
LINGO1 expression in oligodendrocytes has also been shown to negatively regulate 
myelination. One such mechanism that has been suggested is also by activation of RhoA 
and the subsequent inhibition of OPC differentiation to mature myelinating oligodendrocytes 
(Mi et al., 2005). However, recent work suggests that LINGO1 has a dual function as a 
receptor and a ligand, a homophilic intercellular interaction between which mediates OPC 
differentiation and myelination (Jepson et al., 2012). LINGO1 has therefore been suggested 
as a potential target for controlling CNS myelination in disorders such as MS. EAE-induced 
LINGO1 knockout mice, as well as those treated with an anti-LINGO1 antibody, have shown 
marked stabilisation and reversal of disease progression as well as improving axonal health 
and remyelination (Mi et al., 2007).  
1.6 The three AMIGOs 
One family of three LRRIG proteins is the amphoterin-induced gene and open reading frame 
(AMIGO) subgroup, also known as the Alivin’s, which exhibit similar structures and extensive 
sequence homology of around fifty percent (Kuja-Panula et al., 2003). All three are type I 
transmembrane proteins with similar structure to that of the LINGO1, seen in figure 3; a 
single Ig-like domain, an adjacent transmembrane domain and a short cytoplasmic tail, 
however the AMIGOs consist of only 6 extracellular LRR domains. Similarly to LINGO1, the 
family are hypothesised to function as cell adhesion molecules due to their homophilic and 
heterophilic binding capabilities (Chen et al., 2006). However, the AMIGOs are known to 
homodimerise via their LRR regions in order for proper cell surface expression (Kajander et 
al., 2011).  
AMIGO1 is an N-linked glycosylated member of the family (Chen et al., 2012) that was 
originally identified by its upregulation in rat hippocampal neurons when exposed to the 
neurite outgrowth promoting protein amphoterin (HMGB1) (Kuja-Panula et al., 2003). It has 
been suggested that AMIGO1 is important in the survival/proliferation mechanism of HMGB1 
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in zebrafish, and is therefore important in forebrain development. Expression has been 
shown to increase throughout development to a maximum that is sustained into adulthood, 
suggested both a developmental and adult role of the protein  (Chen et al., 2012). Unlike 
AMIGO2 and 3, AMIGO1 is expressed exclusively within the CNS within astroglia, 
oligodendroglia and neurons. Although predominantly dendritic, the removal of the LRR 
domains results in the localisation of AMIGO1 to the axon (Chen et al., 2012). Similarly to 
LINGO1 and other LRRIG proteins, substrate-bound AMIGO1 has been shown to be 
involved in neurite outgrowth in cultured neurons (Kuja-Panula et al., 2003), a depletion of 
AMIGO1 has also been shown to inhibit neurite outgrowth (Chen et al., 2012). The 
expression of AMIGO1 has also been shown to be neuroprotective in vitro (Chen et al., 
2012). 
AMIGO2 was first identified as Alivin-1 (after “alive” and “activity-dependent leucine-rich-
repeat and Ig superfamily survival-related protein.”) for its involvement in depolarisation-
dependent survival of cerebellar granule neurons (Ono et al., 2003). Although AMIGO2 is 
enriched within the hippocampus (particularly Cornu Ammonis 1 and 2, which are particularly 
resistant to neuronal injury and neurotoxicity) it is also enriched within the cerebellum, retina, 
liver and lung. It has been implicated in human gastric adenocarcinoma patients (Rabenau et 
al., 2004) as well as mental retardation (Gimelli et al., 2011). 
 The third member of the AMIGO family, AMIGO3 is particularly understudied, 
although it is ubiquitously expressed with no particular expression patterns (Kuja-Panula et 
al., 2003). Recently, it was shown that AMIGO3 can substitute for LINGO-1 and interact with 
NgR and p75 to signal growth cone collapse (Ahmed et al., 2013b). Knockdown of AMIGO3 
in cell culture demonstrated enhanced dorsal root ganglion neuron neurite outgrowth 
suggesting a direct function in regulating CNS axon regeneration (Ahmed et al., 2013b). It’s 
involvement in MS has also been shown previously suggested within this lab (Ahmed, 
unpublished data). 
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1.7 Aims and hypotheses 
The aim of this study was to investigate the involvement the AMIGO family of proteins in both 
developmental myelination and remyelination during disease. Specifically; 
• To investigate AMIGO expression patterns compared to that of myelination during 
development. 
• To examine AMIGO expression in OLs, OPCs and astrocytes during disease 
progression of EAE. 
• To investigate the effects on differentiation of decreasing AMIGO3 expression in 
oligodendrocyte progenitor cells. 
The major hypothesis of this thesis is that these AMIGO proteins, particularly AMIGO3, are 
expressed by oligodendrocytes and astrocytes and promote OPC differentiation and 
subsequent myelination of axons.  
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2. Materials and Methods 
2.1 Animals 
6-8 week-old female Biozzi ABH mice (Biozzi et al., 1972) were kindly provided by Professor 
David Baker (Queen Mary University of London). Four experimental groups were used each 
consisting of 6 mice, hence a total of 24 mice were used. The groups were defined as: 1), 
healthy controls without EAE; 2), mice at the acute stage of EAE; 3), mice at the first 
symptomatic relapse of EAE; 4), mice at the chronic stage of EAE. 
2.2 EAE induction 
All disease induction methods were licensed by the UK Home Office and approved by Queen 
Mary University of London Ethical Committee. Procedures were performed by Professor 
David Baker. EAE was induced as previously described by Baker et al., 1990 (Baker et al., 
1990). Briefly, mice were injected subcutaneously into the hindflanks with mouse spinal cord 
homogenate dissolved in Freund’s adjuvant, on day 0 and day 7. Animals were then weighed 
and monitored daily for their neurological signs. EAE was scored using a 5-point scale 
(Baker et al., 1990) where 1 = tail paresis, 2 = loss of gait, 3 = complete hindlimb paralysis, 4 
= hindlimb/forelimb paralysis, 5 = death.  
2.3 Tissue preparation 
Animals were killed by CO2 narcosis and perfused intracardially using 4% paraformaldehyde. 
Mice in the acute EAE group were sacrificed during the peak of initial disease (onset of 
complete hindlimb paralysis) at 17 days after disease induction, animals in the relapse group 
were sacrificed at the peak of relapse (day 37 when complete hindlimb paralysis), chronic 
EAE animals were killed at day 65, during which there was hind limb paralysis but no 
recovery. 
2.4 Luxol fast blue (LFB) stain 
Sections were washed in PBS and stained with LFB (Thermo Scientific, UK) solution (0.01% 
w/v in 95% ethanol with 10% acetic acid) at 55°C for 16-24h. The sections were then rinsed 
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in 70% ethanol, differentiated in 0.05% lithium carbonate solution for 4min followed by 70% 
ethanol and stopped with distilled water. Sections were dehydrated with ethanol (70%, 90%, 
100%, 100%), cleared in Histoclear (National Diagnostics, Hull, UK) and mounted with 
Vectamount, all at RT (Vector Laboratories, Peterborough, UK). 
2.5 Immunohistochemistry (IHC) 
Monoclonal antibodies against AMIGO1-3 were from Santa Cruz Biotechnology, Santa Cruz, 
USA (SC-49879, SC-46760, SC-49881); antibody to GFAP was from Sigma, Poole, UK 
(G9269); antibodies to NG2, CaII and MBP were from Abcam, Cambridge, UK (ab101807, 
ab124687, ab40390). Alexa 488-conjugated secondary antibody was from Invitrogen, Paisley, 
UK (A11055) and Texas Red from Invitrogen (T6391). 
Post-natal BALB/c mice (0, 7, 14, 21 and 28 day old) 15µm-thick brain tissue coronal 
sections and 15µm-thick spinal cord tissue sections were fully thawed, washed in PBS and 
permeabilised in PBS containing 0.1% Triton X-100 for 10 min at room temperature (RT). 
After further washes in PBS, sections were blocked in PBS containing 3% BSA and 0.05% 
Tween-20 for 30 min at RT in a humidified chamber.  Sections were then incubated with the 
indicated primary antibodies (1mg/ml) overnight at 4°C (16-18 hr). After washes in PBS, 
sections were subsequently incubated with the appropriately labeled secondary antibody for 
1h at room temp before mounting in VectaShield with DAPI (Vector Labs, CA, USA) and 
visualised using a Zeiss fluorescent microscope equipped with an Axiocam HRC, run through 
Axiovision Software (all from Zeiss, Hertfodshire, UK). RGC5 cultures were treated similarly 
but with primary antibody incubation adjusted to 1h. Negative controls were used in each run, 
which included omission of primary antibody and were used to set the background threshold 
level prior to image capture. 
2.6 Cell culture 
Retinal ganglion cell line (RGC5), initially thought to be RGC from rat retina but later shown 
by several investigators, including the MNG that the cells were oligodendrocyte precursor 
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cells, were grown in 75cm2 culture flask in medium consisting of Dulbecco’s Modified Eagle 
Medium (Invitrogen) containing 5mM Glucose, supplemented with foetal calf serum (10% v/v; 
Invitrogen), penicillin and streptomycin (10% v/v; Invitrogen) and 2mM L-glutamine 
(Invitrogen) in a humidified incubator at 37°C/5% CO2.  
2.7 siRNA-mediated knockdown 
siRNA transfection was carried out using AMIGO3 sense siRNA (5’-
TGGAGGAGCTGGAGAAGTT-3’ (Dharmacon, CO, USA) with Lipofectamine 2000 
(Invitrogen) according to the manufacturers protocol and routinely used in the MNG 
laboratory (Ahmed et al., 2011; Douglas et al., 2009; Ahmed et al., 2013). siRNA (20pmol) 
was introduced to each well of a 8-well chamber slide containing RGC5 cells at 5x103 
cells/well in non-supplemented DMEM (Invitrogen) and incubated for 5h at 37°C/5% CO2. 
Complete RGC5 medium was then added and cells incubated for 48h at 37°C/5% CO2 
before IHC staining was performed to validate immunohistochemical levels of knockdown. 
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3. Results 
3.1 The brain is progressively myelinated during development 
To determine myelination patterns during normal development, studies were conducted 
using primary mouse brain slices from birth to 28 days. Both a traditional staining approach, 
Luxol Fast Blue (LFB), and immunohistochemistry were performed to elucidate myelination 
patterns within the developing brain of postnatal mice; a well documented and recognised 
process.  
The LFB staining revealed typical progressive myelination of the mediolateral corpus 
callosum of mouse coronal sections from p0 to p28 (figure 5). Myelination was first detected 
by LFB at p7, with no staining within the corpus callosum at p0. At p7 several myelinated 
axonal cross-sections were visible. By p14 the number of cross-sections had increased as 
well as the visibility of longitudinal LFB-sensitive axonal sections. At p21 and p28 the number 
of both cross- and longitudinal-myelinated axonal sections did not increase, however the 
strength of the staining clearly did. By p28 the structures of the brain were clearly visible. 
MBP-immunohistochemistry generally showed a similar progressive pattern of increasing 
MBP-positive axons within the mediolateral corpus callosum (figure 6, Red). At p0 small 
distinct MBP-positive regions are visible along the corpus callosum, indicating myelinated 
axonal cross-sections. At p7 these appear to have reduced in number and size, as there is 
minimal MBP-staining throughout the sample. At p14 the corpus callosum is clearly visible as 
a heavily immunostained region, with multiple myelinated cross- and longitudinal axonal 
sections. The number and intensity of these MBP-positive axons continues to increase by 
p21 and p28, by which heavy MBP-staining is visible. 
3.2 The AMIGO proteins are expressed in a similar pattern to myelin production 
during development 
To discover whether the AMIGO proteins were localised to myelinated regions, developing 
mouse brains were fluorescently labelled with antibodies to AMIGO1,2 and 3 as well as MBP.  
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Immunohistochemistry detecting AMIGO3 (figure 6, Green) showed a slightly different 
pattern of staining to that of MBP. At p0 there are very few AMIGO3-positive regions within 
the corpus callosum, with apparently fewer at p7. However, these small regions also showed 
strong myelination, exhibited by strong colocalisation of fluorescence (figure 6, Merge). By 
Figure 5 Progressive myelination of mouse brain from day 0 to day 28 Myelination 
was identified by LFB staining of the corpus callosum (cc) seen in the top right. Boxed 
area on left indicates higher magnification field on right. Black arrows indicate examples of 
myelinated axonal cross-sections. Grey arrows indicate examples of myelinated 
longitudinal axonal sections. Scale bars: 100µm. 
 17 
p14, AMIGO3 presence appears uniformly increased across the whole brain section. 
Apparent visible levels within the partially myelinated corpus callosum were particularly 
elevated. Similarly, areas outside this region showed high levels of colocalisation, although 
AMIGO3 can be observed outside of myelinated regions. At p21 most AMIGO3 is not 
Figure 6 AMIGO3 and MBP expression in mouse brain from day 0 to day 28 MBP (red) 
and AMIGO3 (green) expression was highlighted by immunofluorescent staining of the 
corpus callosum (cc). Boxed area in bottom right indicates higher magnification field. Arrows 
indicate examples of colocalised fluorescence. Scale bars: 50µm. 
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expressed within myelinated regions, as expression is much less generalised than at p14, 
exhibiting smaller highly concentrated regions (mostly outside of the corpus callosum). At 
p28 AMIGO3 expression was again greatly increased within the corpus callosum, by which 
point is highly myelinated. MBP- and AMIGO3-staining patterns at this point appear identical. 
AMIGO1 and AMIGO2 (not shown) showed very similar expression patterns as AMIGO3 
throughout development. 
3.3 The AMIGO proteins are expressed by OPCs, OLs and astrocytes in EAE, 
particularly during relapse 
The cellular expression of AMIGO1-3 was subsequently investigated during the process of 
remyelination, using the MS disease model of EAE in mice. Expression within different cell 
Figure 7 AMIGO3 and NG2 expression in mouse spinal cord during EAE progression 
NG2 (red) and AMIGO3 (green) expression shown by immunofluorescent staining of the 
dorsal column. Boxed area in bottom right indicates higher magnification field. Arrows 
indicate examples of colocalized fluorescence. Scale bars: 50µm. 
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types was examined during the 3 stages of EAE: Acute, Relapse and Chronic. The dorsal 
column of the spinal cord was chosen due to the presence of the posterior column-medial 
lemniscus (PCML) pathway, a pathway composed of large myelinated fibers, of which a 
change in myelination state would be clear. The expression of AMIGO3 in OPCs was first 
investigated as cells that are key to myelination by immunofluorescent staining for neuron-
glial antigen 2 (NG2). Clear populations  
of NG2 glia are present within the dorsal column of control mice (figure 7, Red), which 
appeared to express AMIGO3 (Green). This was particularly noticeable at higher 
Figure 8 AMIGO3 and CaII expression in mouse spinal cord during EAE 
progression caII (red) and AMIGO3 (green) expression shown by immunofluorescent 
staining of the dorsal column. Boxed area in bottom right indicates higher magnification 
field. Arrows indicate examples of colocalized fluorescence. Scale bars: 50µm. 
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magnifications. During acute stage EAE, a reduced number of NG2-positive OPCs were 
present, indicated by a reduction in staining, while AMIGO3 staining is further reduced 
indicating a decreased expression of AMIGO3. It is not possible to elucidate fully whether the 
AMIGO3 expression is from the OPCs during this stage. During the relapse stage of the 
disease there were very few, if any, OPCs present with little AMIGO3 expression. No staining 
was visible by the chronic stage suggesting the absence of NG2-positive OPCs. AMIGO 1 
and 2 expression patterns (not shown) were very similar to those observed for AMIGO3. 
Figure 9 AMIGO3 and GFAP expression in mouse spinal cord during EAE progression 
GFAP (red) and AMIGO3 (green) expression shown by immunofluorescent staining of the 
dorsal column. Boxed area in bottom right indicates higher magnification field. Arrows 
indicate examples of colocalized fluorescence. Scale bars: 50µm. 
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A clear absence of carbonic anhydrase II (CaII)-positive mature oligodendrocytes was 
observed in the dorsal column of control mice (figure 8, Red) with a similar lack of AMIGO3 
expression (Green). During the three disease stages of EAE all visible oligodendrocytes 
expressed AMIGO3 relatively strongly. During the acute stage low numbers of 
oligodendrocytes were observed (particularly within the dorsal column), correlating with low 
levels of AMIGO3 expression. During the relapse stage expression level appeared to be 
highest, with levels outside the dorsal column appearing higher than within. By the chronic 
stage there was again no presence of CaII-positive mature oligodendrocytes or any of the 
AMIGO proteins. 
Figure 10 AMIGO3 and GFAP expression in mouse spinal cord during relapse of EAE 
GFAP (red) and AMIGO3 (green) expression shown by immunofluorescent staining of the 
spinal cord. 
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Within control mice, low numbers of glial fibrillary acidic protein (GFAP)-positive astrocytes 
were present (figure 9, Red). These numbers increased considerably during the acute stage 
of EAE, particularly outside the dorsal column. A further increase was seen when compared 
to the relapse stage, during which astrocyte numbers peaked. By the chronic stage of the 
disease, however, these numbers dramatically decreased, although some still remained. 
Throughout the disease progression (and control) astrocytes expressed AMIGO3 (figure 9, 
Green) although during the acute stage of EAE some cells appeared to express none. The 
number of astrocytes, and also AMIGO3 expression, increased from control to acute to 
relapse and had decreased by the chronic stage. The strong expression of AMIGO3 by 
astrocytes was evident throughout the whole spinal cord during the relapse stage of EAE 
(figure 10). Similar expression patterns were observed for AMIGO1 and 2, suggesting 
astrocytes also produce these proteins. 
3.4 AMIGO3 knockdown did not affect OPC differentiation 
In order to determine the effect of reduced AMIGO3 within OPCs, particularly on 
differentiation, siRNA to AMIGO3 was introduced into the RGC5 cell line. Although classically 
considered a retinal ganglion cell line, RGC5s have recently been proposed to possess 
multiple OPC markers and characteristics (Ahmed, unpublished data). The presence of 
AMIGO3 was determined by immunofluorescent staining of cultures as well as NG2 as a 
Figure 11 siRNA knockdown of AMIGO3 in the RGC5 cell line AMIGO3 (green) , NG2 
(Red, centre) and MBP (Red, right) expression shown by immunofluorescent staining of the 
RGC5 cells. 
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marker for OPCs and MBP as a marker for mature oligodendrocytes and myelin. AMIGO3 
and NG2 expression appeared slightly reduced when compared to that of the negative 
control, although the effect was minimal (figure 11). There was no apparent change in MBP 
expression, which remained low throughout, suggesting no change in differentiation state of 
the cells. 
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4. Discussion 
This study suggests that a group of LRRIG proteins, the AMIGO family, play a novel role in 
the myelination of neurons both during development and after disease-induced breakdown of 
myelin. These proteins are expressed by astrocytes, oligodendrocytes and to a degree 
oligodendrocyte precursor cells. However, the involvement of AMIGO3 in OPC differentiation 
remains unclear. 
4.1. AMIGO proteins are expressed during developmental myelination 
Developmental myelination is known to occur during the late stage of embryo CNS 
development and continue postnatally (Paus et al., 1999). This process was observed within 
the corpus callosum due to being an easily identifiable region of the brain that is known to be 
strongly myelinated. The classical LFB stain validated the use of MBP-targeted 
immunostaining as both showed very similar patterns of staining. The benefit of using 
immunostaining is that two separate antibodies can be used for proteins of interest, a 
technique that was utilised to show correlations between the presence of AMIGO and myelin 
(MBP).  
AMIGO1, 2 and 3 expression was not only seen to increase over time, but the patterns of 
expression matched that of myelin extremely well, evident at 40x magnification. This 
colocalisation provides a basis for a role for these proteins in the developmental myelination 
process. However, at days 7 and 21 this pattern was not followed. The decrease in AMIGO 
expression at day 7 has also been observed in other laboratories suggesting this to be a true 
finding as opposed to an experimental artifact, although no reason for this was suggested 
(Chen et al., 2012). This suggests that the decrease at day 21, and localisation to non-
myelinated regions may also be more than experimental variation. These results suggest 
other possible roles for the AMIGOs as well as myelination.  
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4.2. AMIGO proteins are expressed by cells involved in myelination in EAE 
There is some discussion within the scientific community as to the validity of the 
recapitulation hypothesis of myelination (Fancy et al., 2011). For this reason, both 
developmental and remyelinating processes were observed. The mouse model of EAE was 
used due to it’s similarities to MS in humans (Lassmann, 1983). EAE differs to MS primarily 
by it’s instigation, however the process of demyelination, and particularly subsequent 
remyelination, are thought to be largely similar making it a useful tool within this thesis (Gold 
et al., 2006). Similar to the developmental experiments, fluorescent immunohistochemistry 
was used to observe AMIGO protein expression. This allowed for investigation of AMIGO 
expression by particular cell types by colocalising fluorescence. However it was not possible 
to perform costaining with the anti-NG2 and anti-AMIGO1, 2 and 3 antibodies due to 
interference between the two antibodies. Unfortunately this resulted in a lack of clarity in the 
analysis of AMIGO expression by OPCs. 
During the acute stage of EAE, myelination was expected to be higher than that of the 
control as it is needed to replace that lost during the immune attack. This effect was 
expected to further increase during the relapse as more damage has occurred, meaning 
more myelin to replace. By the chronic stage, as with MS, remyelination was predicted to 
stop (Franklin, 2002). AMIGO expression observed in this study appears to also follow this 
pattern; expression is higher in the acute stage than control, which further increases during 
the relapse stage and with none apparently expressed within the chronic stage. This further 
suggests a role for the AMIGOs in the process of myelination.  
All three AMIGO proteins were expressed by each of the cell types investigated (astrocytes, 
OLs and OPCs), which had only previously been shown for AMIGO1 (Chen et al., 2012). 
Although it is difficult to discern if the OPCs present in the spinal cord express the AMIGOs, 
data using the RGC5 cell line suggest these cells do express at least AMIGO3. Suprisingly, 
the number of OPCs observed through all stages of disease progession was low. 
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Considering that after destruction of myelin mature OLs are unable to produce more myelin 
(Keirsteadand Blakemore, 1997), OPC migration to sites of injury and differentiation into 
mature OLs for subsequent remyelination would be expected to increase. However,control 
tissues showed the highest number of OPCs, which decreased throughout disease 
progression. This may be due to the destruction of OPCs during the course of EAE 
progression or that the majority have differentiated into mature OLs in order to instigate 
remyelination. This would explain the decrease throughout disease progression, as more are 
destroyed or differentiate with increasing severity. 
This is supported by an increase in AMIGO-expressing mature OLs with disease progression 
until at the chronic stage when none were present. This is in agreement with other findings, 
that the number of OLs increases at sites of remyelination and is greater than before 
demyelination (Prayoonwiwat and Rodriguez, 1993). Interestingly though, the numbers within 
the dorsal column are lower compared to those outside, suggesting PCML neurons may be 
less myelinated. The staining also shows the absence of OLs immunoreactivity within control 
mice, this may be due to OLs becoming quiescent and hence losing their reactive phenotype, 
which is then activated after disease. The presence of AMIGO1,2 and 3 in myelinating OLs is 
further evidence for their involvement in the myelinating process. 
The expression of the AMIGOs within astrocytes is the most striking, showing high numbers 
of cells that all appear to express the AMIGO proteins. Replicating previous findings of 
AMIGO1 expression by astrocytes both in culture and in rat brain cryosections (Chen et al., 
2012). The number of astrocytes follows that of OLs, increasing from control to relapse, with 
very few localised during the chronic stage throughout the whole spinal column. Astrocytes 
are important in the promotion of myelinating activity of oligodendrocytes suggesting that the 
AMIGOs may also play a role in the promotion of myelination, although further work is 
required to determine this. 
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The cell markers used for astrocytes, oligodendrocytes and OPCs were anti-GFAP, anti-CaII 
and anti-NG2, respectively, and are well known and used in research (Baumann and Pham-
Dinh, 2001; Sofroniew and Vinters, 2010).  Although they are considered specific, it has been 
suggested that astrocytes, particularly immature cells, can also express CaII (Cammer and 
Zhang, 1992). This may mean that CaII+ AMIGO+ cells may in fact be astrocytes and not 
mature oligodendrocytes and hence differences between these cells will need to be 
confirmed by morphological criteria. However, this is likely to be attributed to a very small 
populaton of cells, and not all of those visible in figure 8.  
4.3. AMIGO3 removal has no effect on OPC differentiation 
It was originally hypothesised that AMIGO3, similarly to LINGO1, may play a role in the 
differentiation of OPCs to OLs. The results of suppressing AMIGO3 expression in the OPC 
cell line showed no real difference to control. This suggests that AMIGO3 is either not 
involved in the differentiation of OPCs or that it in fact promotes the differentiation process. 
The latter would be in keeping with other findings, such as the expression of AMIGO3 by OLs 
and astrocytes. 
siRNA knockdown is a relatively new technique, but is now widely used as it provides a 
simple method of removing a gene in vitro. However, without looking at the percentage of 
protein knockdown it is not possible to discern whether there is in fact no effect on OPC 
differentiation or whether there was a problem with the knockdown procedure. Although a 
protein assay was attempted, no valid results were obtained within the timeframe due to the 
extremely low protein yield obtained from RGC5 cells. It is possible that the RNA did not fully 
bind to that of AMIGO3, therefore not disabling its expression effectively. This could have 
been validated by Western Blot analysis or Bradford assay, although due to time constraints 
these were not performed. siRNA knockdowns are also generally not 100% efficient, if this 
was the case residual activity of AMIGO3 may have been sufficient for normal cell 
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functioning. The activity of AMIGO1 and 2 may also be able to offset the downregulation of 
AMIGO3, although their relative expression levels were not measured. 
The RGC5 cell line used is also not classically an OPC line and was originally described as a 
rat (Rattus norvegicus) retinal ganglion cell line. The cells are now thought to be of mouse 
(Mus musculus) origin and express the neural cell markers "III-tubulin, PGP9.5 and 
microtubule associated protein tau as well as no classical RGC markers (Van Bergen et al., 
2009). Work within this lab suggests that they are in fact OPCs (unpublished data). This is 
supported by previous data that shows RGCs to express AMIGO proteins but not NG2 (Chen 
et al., 2012). However, it is still possible that RGC5 cells do not behave like OPCs in vivo. 
4.4. Possible involvement of the AMIGOs during myelination 
The data collected within this thesis clearly suggests a role for the AMIGO family of proteins 
in the developing, adult and diseased CNS. Further, this data suggests a novel role for the 
AMIGOs in myelination. However, due to the nature of the experiments conducted it is not 
possible to say what the exact role of each protein, or the family as a whole, may be. 
The results suggest a role in promotion of myelination, rather than inhibition like LINGO1. 
This is shown by the highest presence of the proteins when myelination is occurring. If the 
latter were true, no AMIGO protein expression during development would be expected. The 
expression of the AMIGOs by OLs further reinforces this theory, as these are the cells that 
produce the myelin sheath itself. AMIGO1 expression has also been previously shown in 
primary rat neural cell cultures that were selectively enriched in oligodendrocytes (Chen et al., 
2012).  
It is possible that the AMIGO family of proteins not only act in a dissimilar way to LINGO1, 
but that they in fact oppose LINGO1 directly in terms of myelination. AMIGO1 and 2 have 
previously been shown to promote neuronal growth and survival (Chen et al., 2012; Tomio et 
al., 2003) whereas LINGO1 and AMIGO3, as part of the Nogo receptor complex, are known 
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to promote neurite growth cone collapse (Ahmed et al., 2013). It could therefore be 
hypothesised that the AMIGO proteins act as positive regulators of myelination by OLs where 
LINGO1 acts as a negative regulator (Mi et al., 2005). This is in keeping with the results 
observed here. LINGO1 is thought to negatively regulate OPC differentiation and myelination 
by   a   homophilic   intercellular   interaction (Jepson et al., 2012). AMIGO1 is known to 
dimerise via the LRR domain and thought to also interact intercellularly, AMIGO2 and 3 are 
also speculated to act in a similar manner (Kajender et al., 2011). It is possible that the 
AMIGO proteins therefore either disrupt the homophilic interaction of LINGO1 or that their 
own intercellular interactions trigger signaling in an opposing manner to LINGO1. 
LINGO1 is expressed by astrocytes in the demyelinating lesions in the MS brain and thought 
to modulate neuron-glial interactions by interacting with Nogo-A on oligodendrocytes (Satoh 
et al., 2007). Similar interactions could occur between AMIGO proteins, supported by the 
high level of their expression in astrocytes within this study.  
4.5. Future work 
The AMIGO family is a remarkably understudied group of proteins considering the 
implications they have in development and disease. The lack of knowledge about these 
proteins means that there is much further research needed to understand their functioning. 
The results of this thesis suggest a promising novel role of the AMIGOs in myelination, 
however this is just a preliminary study. 
Although the downregulation of AMIGO3 appeared to show no effect, it would also be of 
interest to extend this to the other members of the family. Further the use of a primary OPCs 
would be desirable to reduce any artifacts of the cell line that may adversely affect results. 
Considering the prediction that the AMIGO proteins may also promote rather than inhibit 
OPC differentiation and myelin production it would also be of interest to increase expression 
of the AMIGOs. Investigations with co-cultures of OPCs, astrocytes and neurons could also 
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yield interesting results as to whether the AMIGOs act intercellularly between different cell 
types and if this is necessary for function. 
Blocking the function of the AMIGO proteins by administration of monoclonal antibodies 
during development and EAE would provide valuable information as to their role in 
myelination. If they do function as predicted here, by promoting myelination, the CNS may be 
aberrantly myelinated as well as having maldeveloped neurons. This could be investigated 
by further histological examination. By using antibodies for each of the AMIGO proteins 
individually it would also be possible to see if all had a similar effect, or to the degree in 
which each act. If these results were positive the next stage would be to produce a mouse 
knockout model of the most critical AMIGO proteins, or conditional knockout if the former 
proves fatal. This would allow a whole host of further examination to be carried out, from 
OPC differentiation to neurite outgrowth. 
In order to investigate whether the AMIGO proteins also act via the same mechanistic 
pathway as LINGO1, binding studies, such as co-immunoprecipitation or yeast two-hybrid 
assays, with members of the Nogo signaling pathway could also be investigated. 
4.6. Concluding remarks 
Research into the role of the AMIGO family of proteins is very much in its infancy. Current 
work suggests members of the family are required for brain development (Zhao et al., 2011), 
are involved in axonal and dendrite outgrowth (Kuja-Panula et al., 2003; Chen et al., 2012) 
and promote survival of neurons (Ono et al., 2003). The data presented here suggests a 
novel role for this group of proteins as regulators of both developmental myelination and 
remyelination during EAE. AMIGO1, 2 and 3 expression is shown in both the developing, 
adult and diseased CNS of mice and their expression by several cell types involved in 
myelination. Reduction in AMIGO3 expression was also found to have no effect on OPC 
differentiation. Although preliminary, this work therefore suggests the AMIGO family as 
potential novel targets for therapy for demyelinating disorders such as MS. 
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Abstract 
Evidence suggests that both mesenchymal and hematopoietic stem cells (MSCs and HSCs, 
respectively) can alter an inflammatory environment in vivo by secretion of inflammation-
modulating agents. This was examined by first developing an in vitro model of inflammation 
and subsequently adding stem cell (SC) conditioned media . Addition of basal MSC and HSC 
conditioned media increased Kc-activated neutrophil adhesion to TNF-!-activated colon and 
renal endothelium, respectively. This increase in adhesion was further enhanced when using 
media from SCs, which were stimulated prior to media generation. H2O2-treatment of MSCs 
and TNF-!-treatment of HSCs significantly increased neutrophil adhesion to renal 
endothelium compared to PBS-treated control. Similarly, when activated neutrophils were 
further treated with MSC conditioned media, adhesion to VCAM-1, ICAM-1, MAdCAM1 and 
hyaluronan increased. However, neutrophils treated with MSC conditioned media showed a 
decrease in adhesion to the immobilised protein ligands. Similarly H2O2- and TNF-!-MSC-
treatment led to the significant changes in the neutrophil adhesion modulating capabilities of 
the supernatant. Untreated HSC conditioned media, and H2O2- and IFN-"-treated HSC 
conditioned media treatment of neutrophils resulted in significant decreases in adhesion to 
immobilised protein ligands.  This data suggest that MSCs and HSCs have multiple effects 
on inflammation. 
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1. Introduction 
4.1. Inflammation 
Inflammation is a protective vascular tissue response to harmful stimuli, such as infection, 
irritation or physical damage. It is an immediate, localised response involving the immune 
system with the aim to remove the stimuli and initiate repair of damaged tissue. However, the 
process becomes dysregulated it can prove to be detrimental (Medzhitov, 2008).  
The classic inflammatory response can be classified as either acute or chronic. During acute 
inflammation, endothelial cells are rapidly activated by inflammatory mediators, such as 
cytokines, which induces a range of characteristic responses. . Gaps open between 
endothelial cells allowing plasma proteins to pass through from the circulatory system into 
the damaged extravascular tissue. The matrix formed by these plasma-proteins supports the 
entry of leukocytes, primarily neutrophils (Pober and Sessa, 2007).  
The mechanism by which neutrophils are recruited from the blood flow in order to cross the 
endothelium and enter the inflamed tissue occurs via the neutrophil adhesion cascade., 
shown in figure 1. This process consists of four defined stages, although others have been 
proposed (Ley et al., 2007), namely rolling, activation, firm adhesion and migration (Butcher, 
1991). Each distinct stage requires different cell adhesion molecules (CAMs) in order to 
facilitate successful recruitment. Initially, neutrophils roll along the vessel wall, slowing their 
speed relative to blood flow and facilitating rolling. This stage is mainly reliant on selectins: a 
group of Ca2+-dependent molecules present on the surface of activated vascular endothelium 
and the circulating leukocytes. Once slowed from flow, inflammatory cells roll along the 
endothelium and interact with the inflamed endothelium via transient selectin bonds to 
glycosylated ligands such as P-selectin glycoprotein ligand 1 (Ley et al., 2007). These 
interactions have extremely high on- and off-rates, allowing the cells to adhere to the 
endothelium from flow. Subsequently, cytokines released from the endothelium activate 
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leukocytes.. This process is particularly rapid and can occur in under a minute (Peled et al., 
1999). Activated neutrophils and leukocytes upregulate adhesion molecules known as 
integrins, which facilitate their firm adherence to the endothelium. The integrins bind 
specifically to CAMs expressed by the endothelium, which belong to the immunoglobulin 
superfamily (IgSF). The key CAMs for firm adhesion are vascular cell adhesion molecule-1 
(VCAM-1), intercellular adhesion molecule-1 (ICAM-1) and mucosal addressin cell adhesion 
molecule-1 (MAdCAM-1) (Barclay, 2003).  The glycosaminoglycan hyaluronan (HA) has 
been shown to play an important role in leukocyte recruitment, although this is not a member 
of the IgSF (Kessler et al., 2008). Following firm adhesion, leukocytes transmigrate through 
the endothelial layer, then through the basement membrane and ultimately into inflamed 
tissue. 
Recruited neutrophils are further activated within the damaged tissue by either coming into 
direct contact with a pathogen (if caused by infection) or by the actions of locally produced 
cytokines by tissue-resident cells (Medzhitov, 2008). The activated neutrophils then clear any 
invading organisms or damaged cells by releasing the toxic contents of their granules, such 
Figure 1 Leukocyte adhesion cascade The four main stages of leukocyte adhesion during 
inflammation are shown with illustrative examples of the CAMs and agents involved. Adapted 
from Butcher and Picker, 1996. 
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as NADPH oxidase, which generate reactive oxygen species (ROS). This process is 
indiscriminative resulting in destruction of healthy host tissue as well as the harmful stimuli 
(Nathan, 2002). Acute inflammation resolution is triggered by the neutrophils a few hours 
after initiation of inflammation. Neutrophils promote a change in local environment from 
prostaglandins to lipoxins while resolvins and protectins are also synthesised, initiating the 
termination sequence and preventing further neutrophil recruitment and engaging apoptosis 
(Serhan and Savill, 2005). The neutrophils are subsequently cleared by macrophage 
phagocytosis while anti-inflammatory and reparatory cytokines are released, finally followed 
by macrophage clearance through the lymphatic system (Bellingan et al., 1997).  
If the acute inflammation is not resolved, a chronic state of inflammation may ensue. In fact 
some pathologies tend to cause a chronic, rather than acute, inflammatory state by their 
nature. A non-resolving inflammatory process results in a switch from a primarily neutrophil 
driven inflammation to a macrophage/lymphocyte driven inflammation (particularly T-cells). 
T-cells are known to activate macrophages, which is a particular problem in autoimmune 
disease. The phagocytosing macrophages also secrete inflammatory paracrines and growth 
factors that may result in the formation of granulomas. 
1.1 Renal and Colonic inflammation 
Inflammatory disorders are known to affect almost all tissue types, including both the kidney 
and the colon. Renal inflammation, or nephritis, is the number 5 cause of renal failure in the 
US (Kidney Trust, 2013). Nephritis is the activation of the renal endothelium, resulting in the 
proliferation and accumulation of inflammatory cells leading to disturbance of the glomerular 
structure. This can be either inflammation of the glomeruli (glomerulinephritis) or of the 
region between tubules (interstitial nephritis). Disruption of the kidney can result in the 
accumulation of urea and other nitrogen-containing substances in the blood as well as 
proteinuria (the presence of increased serum proteins in the urine) both of which can have 
serious consequences including stroke and renal failure (Haroldsson et al., 2008). Two of the 
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most common causative agents in establishing nephritis are infection and autoimmune 
response. Regardless of causative mechanism, the characteristics of nephritis are broadly 
similar, although severity differs. Many cases of nephritis resolve spontaneously, however 
many will follow full disease progression from acute to chronic inflammation. In many cases 
this will result in irreversible damage and renal failure. Treatment aids many patients before 
this stage, yet nephritis and nephropathy still accounts for 1.19% of total deaths worldwide 
(WHO, 2004) suggesting a need for further treatment options. 
Inflammation of the colon is one of the primary causes of inflammatory bowel disease (IBD) 
and is known to affect around 1.4 million Americans, and similarly to other Western countries, 
that figure is rising (Abraham and Cho, 2009). Two of the main causes of IBD, Crohn’s 
disease and ulcerative colitis, are classified as idiopathic (no specific cause is known). One 
theory proposes that genetic susceptibility leads to an inappropriate inflammatory response 
to bacteria in the gut in these chronic disorders (Abraham and Cho, 2009). As no definitive 
cause is known, treatments range from symptomatic agents to anti-inflammatory treatments. 
Anti-inflammatory agents commonly used include corticosteroids and cytokine neutralising 
antibodies such as infliximab. Many of these therapeutic agents remain inadequate, can 
cause undesirable side effects and must be used for prolonged periods, suggesting a need 
for new treatments. 
1.2 Stem cells 
Stem cells (SCs) have a unique ability self-renew as well as differentiate into a multitude of 
other specialised cell types (potency), as well as other SCs. Mammalian SCs can be 
classified as embryonic, hailing from blastocysts, or adult, which are found throughout a 
variety of tissues. Since the discovery that some cell types can produce others in the mid 
1800s, there have been many ideas and much controversy over SCs. Bone marrow (BM) 
transplants, normally consisting of the allogenic transplantation of adult stem cells (ASCs) 
into recipients, have been used since the mid 1900s for treatment of immunodeficiency 
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disorders. Embryonic SCs, however, are a more recent discovery and have only been used 
since their isolation in 1998. In more recent times, our knowledge of SC biology has 
advanced greatly, but there still exists many conflicting views of how they function and the 
potential therapeutic uses may be. 
The regenerative capacity of stem cells to repair damaged or lost tissues by differentiation is 
a very attractive property for therapy. Hematopoietic stem cell (HSC) transplantation by BM 
transfer is still widely used to treat leukemia and lymphoma patients to replace their 
dysfunctional immune cells that have been destroyed by cytotoxic chemotherapeutic agents 
or radiation therapy. This treatment is advantageous as there is no need for expansion of 
cells in culture prior to use and also no need to reconstitute a multicellular tissue prior to 
transplant. Research in the field of SCs is advancing to provide autologous grafts for 
treatment of wounds such as burns (Green, 2008) and damaged corneas (De Luca et al., 
2006). Use of ex vivo autologous SCs, although requiring expansion, offers potential 
treatment without fear of rejection. Gene therapy has also been used within the clinic 
combined with SCs in order to produce modified cells in which a defective gene has been 
corrected (Watt and Driskell, 2010). SC research also appears positive for treatment of many 
disorders, such as cardiomyopathy (Jakob and Landmesser, 2013), osteoporosis (Jazedje et 
al., 2012), and autoimmune diseases (Jakob and Landmesser, 2013).  
In many damaged tissues, however, engraftment of ex vivo isolated/expanded SCs is not 
possible. However, stem cells have been proposed to naturally mobilise from their niches to 
sites of injury or tissue regeneration (Kavanagh and Kalia, 2011). This process has been 
shown in a wide variety of injuries, from amputation (Guedelhoefer and Alvarado, 2012) to 
tissues damaged through degeneration, ischemia and inflammation (Kavanagh and Kalia, 
2011). If this process can be harnessed then external SCs may not need to be administered, 
and a patients own SCs may be mobilised to the site of injury.  
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Recently, a large interest has been taken in the other properties of SCs since they have been 
suggested to produce antibacterial defences through the secretion of antimicrobial peptides 
(Krasnodembskaya et al., 2010) as well as exhibiting anti-inflammatory effects after injury 
(Tögel et al, 2005; Kavanagh et al., 2013). Recent advancements in SC function in injury 
have concentrated on two types of SCs; mesenchymal stem cells (MSCs) and HSCs. 
1.3 Mesenchymal and hematopoietic stem cells 
The majority of ASCs used in research are sourced from BM. Within the BM exists two main 
subsets of stem cells: mesenchymal and hematopoietic. Mesenchymal stem cells (MSCs) 
are a self-renewing multipotent subset of stromal stem cells that differentiate primarily into 
cells of the mesodermic lineage: osteoblasts, chondrocytes and adipocytes (Ucelli et al., 
2008). They are defined as cells that have fibroblast-like morphology that proliferate in vitro 
as plastic-adherent colonies and express CD105, CD73 and CD90 while lacking expression 
of CD45, CD34, CD14 or CD11b, CD79a   or CD19 and HLA-DR surface molecules 
(Dominici et al., 2006). Although BM-derived cells that are plastic-adherent are widely used 
in research as mesenchymal stem cells, not all these isolates necessarily meet specific SC 
criteria but are still referred to under the acronym MSC, for multipotent mesenchymal stromal 
cell (Horwitz et al, 2005). MSCs have also been sourced from a large number of other 
tissues with generally similar gene expression patterns, however slight differences are 
exhibited (Otto and Wright, 2011).  
As well as cells of the mesoderm lineage, MSCs have been recorded to transdifferentiate 
into cells of the ectodermic (Peterson et al., 1999) and neuroendodermic lineages (Pittenger 
et al., 1999), such as epithelial, muscle and even neuronal cells. It has been suggested that 
MSCs could be used for regeneration of almost any tissue, however results are often 
inconsistent (Uccelli et al., 2008).  
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Since the discovery that MSCs suppressed T-cell proliferation (Di Nicola et al., 2002) the 
majority of MSC-related research has investigated their broad range of immunomodulatory 
activities.  In vitro MSCs have been shown to inhibit T-cell proliferation and production of pro-
inflammatory cytokines (Di Nicola et al., 2002) as well as inhibiting the generation and 
function of dendritic cells (Nauta et al., 2008) and inhibiting antibody production by B cells 
(Comoli et al, 2008). On the other hand, some groups have shown MSCs to have opposite 
effects, thus promoting T-cell survival (Benvenuto et al., 2007) as well as stimulating their 
activation and proliferation independently of cell contact (Crop et al., 2010). This 
contradiction of ideas shows a clear need for further research into the immunomodulatory 
properties of MSCs, especially before use as in the clinic. 
The other main group of BM-derived adult stem cells are HSCs, which constitute around one 
in every thousand bone marrow cells (Schroeder, 2010). HSCs are also self-renewing BM-
derived stem cells, which primarily differentiate into a variety of blood cells of both the 
myeloid and lymphoid lineages. There are three subtypes of HSC; balanced HSCs (which 
repopulate white blood cells of both lineages equally), lymphoid-biased and myeloid biased 
(Schroeder, 2010). Each are considered normally functioning cells. HSCs are ordinarily 
maintained in pools within HSC niches in the bone marrow. Cells normally reside within their 
quiescent state until intrinsic or extrinsic signals trigger a response (Chotinantakul and 
Leeanansaksiri, 2012). Once triggered, stem cells are able to mobilise into the peripheral 
blood system.  
As previously mentioned, HSCs, via BM transplantation, have classically been used to treat a 
wide range of haematological and immune deficiency disorders, particularly to aid recovery 
after bone marrow ablative cancer treatment. However, HSCs may possess some plasticity 
and can also transdifferentiate into other specialised cell types, including cardiomyocytes 
(Pozzobon et al., 2010), endothelial cells (Elkhafif et al., 2011) and adipocytes (Sera et al., 
2009). HSCs also appear to mobilise to sites of injury (Kavanagh and Kalia, 2011). For this 
 8 
reason circulating HSCs have also been manipulated to repair damaged solid-organ tissue in 
conditions as varied as myocardial infarction (Orlic et al., 2001), chronic limb ischemia 
(Tateishi-Yuyama et al., 2002) and neurodegenerative disorders (Mezey et al., 2003). 
Similarly to MSCs, much research has been conducted into the immunomodulatory effects of 
HSCs, often with conflicting results. This may be due to the isolation techniques employed 
and the resulting population of hematopoietic tissue, which may contain a variety of other 
cells, including some MSCs along with other contaminating cells. Furthermore, a number of 
groups use different sources and preparations of the HSCs, which could further exacerbate 
differences in results (Kørbling and Estrov, 2003). Once in the blood, HSCs protected from 
phagocytosis by macrophages through CD47 signalling (Chao et al., 2012). They are also 
known to be immune to pathogen infection in vitro (Kolb-Mäurer et al., 2002). It has been 
suggested that HSCs are the first responders to an infection, and their differentiation is 
regulated by pro-inflammatory cytokines such as tumour necrosis factor-! (TNF-!) and type I 
and II interferons (IFN) (King and Goodell, 2011). Importantly, HSCs have also been shown 
to secrete such pro- and anti-inflammatory cytokines and growth factors, such as TNF-!, 
stem cell factor (SCF) and transforming growth factor-#1 (TGF-#1) (Granick et al., 2012). 
HSCs can also control T-cell proliferation by upregulating CD274 expression (Zheng et al., 
2011).  
1.4 Stem cell therapy in renal and colon injury 
In vivo studies, particularly within injured colon, have shown conflicting results for tissue 
repair. MSCs have been shown to reduce ameliorate DSS-induced colitis in rats via anti-
inflammatory action (Tanaka et al., 2008). Similarly, DSS-induced colitis has been shown to 
be worse in BM-depleted rats, with at least partial rescue by the addition of MSCs (Yabana et 
al., 2009). However, MSC some have suggested that the presence of MSC may be 
detrimental to tissue health. The number of tumours in a model of fibromatosis of the 
intestines has been shown to correlate directly with the number of immature MSCs present 
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(Wu et al., 2010). It should be noted that it is suggested that this is not an effect mediated by 
MSCs alone; interactions between the endothelium and MSCs, keep MSCs in their immature 
state and allowing continued fibromatosis growth (Otto and Wright, 2011).  
Studies examining the use of HSCs in renal injury have also shown similarly conflicting 
results as those found with MSCs in the colon. HSC mobilisation has been reported by some 
as detrimental to kidney regeneration (Tögel et al., 2004) while others have suggested that 
HSC mobilisation can be renoprotective in acute kidney injury (Fang et al., 2005). Much work 
has been conducted with crude isolates of BM-derived stem cells and beneficial effects 
attributed to MSCs, but this may in fact be the work of HSCs present in the BM suspension 
(Bussolati et al., 2008).  
Work within this laboratory has shown that HSCs can be recruited to sites of ischemia-
reperfusion injury in the colon and kidney (Kavanagh et al., 2012; White, PLoS ONE, in 
press). Once at the site of injury, HSCs are seen to dampen the inflammatory response, 
observed as a decrease in leukocyte adhesion (Kavanagh et al., 2013; White, PLoS ONE, in 
press). However, in some cases, recruitment instigated by injury alone is insufficient for 
mediating anti-inflammatory effects of the disorder and pretreatment with cytokines or 
chemokines is necessary (Kavanagh et al., 2013). This pretreatment does not appear to 
increase surface expression of adhesion molecules but does increase the surface integrin 
expression (Kavanagh, 2013).  
1.5 Summary 
Inflammatory disorders are an increasing problem within the Western world, particularly of 
the colon and kidney suggesting a need for newer, more effective treatments. Cellular 
therapy, through HSCs and MSCs, show a great deal of promise for such treatment. 
Although SCs are making their way into the clinic, much is still unknown about their function, 
which may lead to unforeseen complications and suboptimal use of this treatment modality. 
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Therefore there is a need for more basic studies into their inflammation-mediating behaviour 
and work to optimise their potential as therapeutic agents in inflammatory disorders. 
1.6 Aims and hypothesis 
The main hypothesis of this thesis is that MSCs and HSCs alter the inflammatory 
environment at sites of inflammation, and that pretreatment of these cells will alter this effect. 
More specifically the aims are: 
• To develop an in vitro method for determining an alteration in inflammatory 
environment. 
• To measure the change in inflammation caused by MSCs and HSCs with and without 
pretreatment. 
• To discern whether any effect is due to actions between stem cells and endothelium, 
stem cells and leukocytes or both. 
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2. Materials and Methods 
2.1 Neutrophil Isolation 
Neutrophils were isolated from the femurs and tibias of donor C57BL/6 mice. Animals were 
sacrificed via cervical dislocation followed by detachment of hind limbs from the pelvis. 
Bones were cleaned by careful physical removal of muscle and connective tissue. The 
epiphysis of each bone was removed under sterile conditions and bone marrow removed by 
flushing through with EDTA (0.01% in PBS) using a 25G needle. Aggregations were 
mechanically separated by passage through a 19G needle and the resulting suspension 
passed through a 70µm filter. Cells were pelleted by centrifugation (300g, 5mins, room 
temperature (RT)) and resuspended in EDTA (0.01% in PBS) prior to treatment with 4ml of 
ice-cold water for 30 seconds to lyse erythrocytes. Cells were again pelleted (300g, 5mins, 
RT) following restoration of isotonicity with 2ml of 4x PBS and resuspended in EDTA (0.01% 
in PBS). A Percoll (Sigma-Aldrich, Poole, UK) gradient column was prepared of 72%, 64% 
and 52% (v/v) in PBS from a stock isotonic solution of Percoll (9 parts v/v Percoll to 1 part v/v 
10x PBS). Cell suspension was loaded onto the column and spun for 30mins at 1500g at 
room temperature. A distinct band of neutrophils should form at the barrier between the 72% 
and 64% Percoll solutions. Cells were washed twice by centrifugation (300g, 5mins, RT) with 
Ca2+/Mg2+ free PBS supplemented with 0.1% BSA before being resuspended in Ca2+/Mg2+ 
containing PBS supplemented with 0.1% BSA. 
2.2 MSC Isolation 
MSCs were isolated as previously described (Morikawa et al., 2009). Tibias and fibias were 
removed as above and washed thoroughly with PBS. Bones were then ground with a pestle 
and mortar and washed again with 5ml PBS. Bones were incubated in 20ml collagenase 
(0.2% in DMEM) for 1 hour at 37°C on an orbital shaker between 100-120rpm before placing 
into ice. All subsequent steps were also performed on ice. Suspension was passed through a 
70µm filter, keeping bones in mortar. Bones were tapped to release cells before media was 
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removed and filtered again. 2.5ml of ice-cold HBSS media was added supplemented with 
FBS (2%), penicillin (50U/ml), streptomycin (50U/ml), L-Glutamine (2mM) and HEPES 
(10mM) and tapping repeated. Solution was passed through a 70µm filter cells pelleted 
(280g, 7mins, 4°C). Supernatant was discarded and cells resuspended in media remnants. 
Red blood cells were lysed by addition of 1ml sterile water for 1 second before addition of 
1ml of 2x PBS containing FBS (4%). The resulting solution was made up to 20ml with HBSS, 
filtered and centrifuged (280g, 5mins, 4°C). Supernatant was discarded and pellet 
resuspended in 1ml HBSS. Single colour controls were prepared by addition of 4µl of cell 
suspension to 4 x FACS tubes containing 100µl HBSS. 1µl of the relevant antibody was 
added to each single colour control (Sca-1/FITC, CD45/PE, TER119/PE, CD140a/APC). . All 
antibodies were added to the main cell suspension (1µl for FITC- and PE-labeled antibodies 
and 2µl APC-labeled antibodies per mouse). Suspension was vortexed and incubated for 
30mins on ice. HBSS was added (1ml to single colour tubes, 10ml to suspension), vortexed, 
and centrifuged (280g, 5mins, 4°C). Supernatant was discarded and main pellet 
resuspended in HBSS containing PI. Labelled MSCs were isolated using flow cytometry. 
2.3 Cell Culture 
An embryonic murine hematopoietic progenitor cell line, HPC-7, was used for all HSC 
experiments within this thesis (Professor Leif Carlsson, University of Umeå, Sweden). Cells 
were cultured in StemPro-34 Serum Free Medium (Life Technologies, Paisley, UK) 
supplemented with penicillin (50U/ml), streptomycin (50U/ml), L-Glutamine (2mM) and SCF 
(100ng/ml, Invitrogen). Cells were maintained daily at a density of 1 x 106 cells/ml. 
Primary MSCs were cultured in !MEM (Life Technologies) supplemented with FBS (10%), 
penicillin (50U/ml), streptomycin (50U/ml), L-Glutamine (2mM) and TGF#  (10ng/ml) and 
incubated at 37°C with 5% CO2. 
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Immortalised renal and colonic endothelial cells were isolated from the ImmortoMouse 
(Jat et al., 1991). These cells were obtained as a kind gift from Dr. J. Steven Alexander 
(LSU-HSC, Los Angeles, USA). Endothelial cells were cultured in flasks precoated with 
gelatin (2%, from porcine skin, Sigma) in growth media consisting of D-valine MEM 
(PromoCell, Germany) supplemented with FBS (10%), penicillin (50U/ml), streptomycin 
(50U/ml), L-Glutamine (2mM), non-essential amino acids (1%), MEM vitamin solution (1%, 
Gibco, Invitrogen) and mouse IFN" (10units/ml) and incubated at 33°C with 5% CO2.  
Before use, endothelial cells were transferred to 24-well plates precoated with gelatin for 5-
10mins (2%, porcine skin, Sigma) in experimental media consisting of high glucose DMEM 
(Sigma-Aldrich) supplemented with FBS (10%), penicillin (50U/ml) and streptomycin (50U/ml) 
and incubated at 37°C with 5% CO2. 
2.4 Cell Counting 
A standard Neubauer haemocytometer was used for all cell counting. Cell suspensions were 
diluted 1:1 (v/v) with Trypan blue in order to indicate dead cells that could then be excluded 
from the final count. Approximately 10µl of solution was viewed under a 10x objective. An 
average number of viable cells was calculated from four grid fields accounting for dilution and 
multiplied by 1x104 to yield the number of cells per ml. 
2.5 Conditioned Stem Cell Media Preparation 
For both HSCs and MSCs, three types of conditioned media were produced: pre-treatment 
media (PreTM), treatment-containing media (TCM) and post-treatment media (PostTM). 6 
treatments were applied to the stem cells: PBS, CXCL1 (Kc), stromal cell-derived factor-1! 
(SDF-1!), H2O2, interferon-" (IFN-") or tumour necrosis factor (TNF-!).  
5ml of HPC-7 in experimental media were placed in a T25 flask at a density of 1x106 cells/ml. 
After 24 hours, the cell suspension was removed and centrifuged to pellet cells (300g, 5mins, 
RT). Media was removed and retained as PreTM. Cells were subsequently resuspended in 
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5ml of experimental media containing treatment (25ng/ml) or an appropriate amount of PBS 
as control. After 24 hours,  the media was removed and retained as TCM media and cells 
were again resuspended in 5ml experimental media not containing treatment. After another 
24 hour incubation period the media was collected as PostTM and cells discarded. This 
process was repeated three times to ensure reliability of results. All media was stored at -
20°C in 100µl or 500µl aliquots for use at a later date. 
Primary MSCs were plated into a T25 flask and at confluence, the same procedure as 
above was carried out. As MSCs are adherent cells, the media was removed and cells were 
washed with PBS at each stage.  
2.6 Fluorescent Neutrophil Labelling 
Cells were labeled using 5’6-carbxyfluorescein diacetate succinimidyl ester (CFDA-SE). 
CFDA-SE is a cell permeable dye that is intracelullarly cleaved by esterases to a fluorescent 
molecule, CFSE. Neutrophils were suspended in 2ml PBS (containing Ca2+/Mg2+) 
supplemented with 0.1% BSA. 2ml of PBS containing CFDA-SE (10µM) was then added to 
the cell suspension and incubated for 15mins at room temperature in the dark. Staining was 
quenched with 6ml of neutrophil media consisting of DMEM (Invitrogen) supplemented with 
FBS (10%), penicillin (50U/ml), streptomycin (50U/ml) and L-Glutamine (2mM). Cells were 
then washed twice by centrifugation in neutrophil media (300g, 7mins, RT) and recounted. 
Cells were diluted to 2x106 per ml for pretreatment or adhesion assay. 
2.7 Stimulation of Neutrophils 
Neutrophils were stimulated after fluorescent labelling by one of 6 pretreatments: PBS, Kc, 
SDF-1, H2O2, IFN-" or TNF-!. Treatments were prepared in neutrophil media at double 
concentration (200ng/ml) and added to cell suspensions of 2x106 cells/ml (also in neutrophil 
media) in a ratio of 1:1 (v/v). This solution was incubated in the dark for 20mins at room 
temperature. 
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2.8 Adhesion Molecule Static Adhesion Assay 
Flat bottomed 96-well plates were coated with one of four adhesion molecules: vascular cell 
adhesion molecule-1 (VCAM-1, 10µg/ml), intercellular adhesion molecule-1 (ICAM-1, 
10µg/ml), mucosal vascular addressin cell adhesion molecule-1 (MAdCAM-1, 10µg/ml) or 
hyaluronic acid (HA, 0.5mg/ml). Plates were incubated for 1h at room temperature. Adhesion 
molecules were then aspirated, the plates washed with PBS. Plates were then blocked with 
1% heat-denatured BSA in PBS for one hour at room temperature. 
1 x 105 neutrophils were loaded into each well and incubated for 20mins at room temperature. 
Where appropriate, conditioned media was also added simultaneously (100µl). After 
incubation, cell suspension was aspirated and washed three times with PBS carefully to 
avoid detachment of adherent cells by rough handling. Adherent neutrophils were then fixed 
by incubation with formalin solution (5%, Sigma-Aldrich) for 15mins at 37°C. Wells were 
washed three times with PBS before the addition of 100µl PBS. Plates were then stored at 
4°C until ready for analysis. 
2.9 Endothelial Cell Static Adhesion Assay 
24-well plates were precoated with gelatin (2%, porcine skin, Sigma) to aid endothelial cell 
adhesion. This was then aspirated and washed with PBS to remove excess. Endothelial cells 
(either kidney or colon) were grown to confluence in experiment media at 37°C with 5% CO2. 
Media was removed from the monolayers and washed with PBS. Endothelial cells were 
activated with TNF! (100ng/ml in fresh media) for 4 hours at 37°C. Media was then removed, 
monolayers washed with PBS and 5 x 105 fluorescently stained neutrophils activated with Kc 
added (in 500µl neutrophil media). Conditioned stem cell media was simultaneously added in 
a ratio of 1:1 (v/v) and incubated at 37°C for 30mins to allow transendothelial migration. 
Following this period, media was removed and cells washed three times with PBS before 
incubation with formalin solution (5%, Sigma-Aldrich) for 15mins at 37°C. Cells were again 
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washed three times with PBS before the addition of 500µl PBS. Plates were then stored at 
4°C until ready for analysis. 
2.10 Imaging and Analysis 
All imaging was performed using an EVOS FL cell imaging system (Life Technologies, UK). 5 
separate fields of view were selected for all static adhesion assays using a set pattern for 
consistency. An initial field was chosen in the center of either the 96- or 24-well plate as well 
as adjacent fields above, below and to the left and right of this initial field. The number of 
adherent fluorescent cells was counted using ImageJ analysis software (Wayne Rasband, 
NIH, US). Non-fluorescent cells were counted by hand. 
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3. Results 
3.1. Gr-1 positive neutrophils can be isolated in sufficient number and purity from 
the murine bone marrow 
In order to investigate inflammation effectively, it was important to know that the neutrophils 
could be cells isolated from BM in sufficient number and at sufficient purity. Flow cytometric  
analysis was used with Gr-1 as a marker of neutrophils. 75.16% of the total viable cells 
analysed were Gr-1-positive compared to 0.21% of the IgG control (Figure 2A and B). This 
was deemed acceptable evidence for the isolated cells to be used as neutrophils. On 
average one mouse yielded approximately 8,000 neutrophils. 
3.2. Neutrophil adhesion to CAMs is not significantly altered by CFSE 
Staining of the isolated neutrophils within experiments was important to permit simple 
quantitative analysis. In addition, we investigated whether staining cells with CFSE led to 
increased adhesion. To investigate this, a static adhesion assay was conducted with 
unactivated stained and unstained neutrophils.  Although there was a slight numerical 
reduction, staining of neutrophils with CFSE did not significantly alter their adhesion to 
immobilised protein ligands (Figure 2E-H).  Figure 2C and D show an illustrative example of 
stained and unstained neutrophils adherent to VCAM-1.  
3.3. Neutrophil adhesion to CAMs is significantly increased by Kc 
In order to model in vivo inflammatory conditions, a mechanism for activating neutrophils was 
required. In order to investigate this, neutrophils were incubated with a selection of cytokines, 
chemokines and reactive oxygen species (ROS) prior to CAM static adhesion assays (Figure 
2A-D).  Kc pretreatment of neutrophils led to a significant, almost three-fold increase of 
adhesion to VCAM-1 (normalised adherent cells: PBS: 2.66±0.62 vs Kc: 6.88±0.56, P<0.01; 
Figure 3A). Although H2O2 and IFN" led to increases in adhesion to VCAM-1, these 
differences were not significant (Figure 3A). Levels of neutrophil adherence on VCAM-1 
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following TNF-! or SDF-1! treatment were similar to PBS. Although neutrophil adhesion to Figure 2 Flow cytometric analysis of neutrophils and neutrophil CAM ad esion assays
after staining (A) Flow cytometry dot plot from a single cell suspension of BM-derived 
neutrophils labelled. The highlighted area shows viable cells. (B) Gr-1 flow cytometry 
histogram is shown from viable cells. The black line represents Gr-1 positive cell; the grey 
line represents the negative control (n=1). (C) Representative image of unstained neutrophils 
adhering to VCAM-1. (D) Representative image of stained neutrophils adhering to VCAM-1. 
(E-F) Number of stained and unstained neutrophils adherent to VCAM-1, ICAM-1, MAdCAM-
1 and HA normalised to BSA control ± SEM. (n=4 prior to removal of statistical outliers 
(P>0.05)). Statistical significance was calculated by unpaired t-test, no significant difference 
was detected. 
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MAdCAM-1 was higher following H2O2 and IFN-" treatment, these increases were not 
significant (Figure 3C). No pre-treatment strategy significantly altered the adhesion of 
neutrophils to either ICAM-1 or HA (Figures 3B and D). Kc pre-treatment was used in 
subsequent experiments to activate neutrophils. 
3.4. Neutrophil adhesion to endothelium in vitro is not significantly affected by 
pretreatment but is proportional to the number of cells applied 
During inflammation in vivo, both endothelial cells and neutrophils are activated. The effect of 
this on neutrophil adhesion was therefore investigated. Combinations of Kc-treated 
neutrophils were added to TNF-!-treated renal and colon endothelium (Figures 4A and B 
respectively). Activation of colonic endothelium or neutrophils increased neutrophil adhesion 
Figure 3 Neutrophil pretreatment CAM adhesion assays (A-D) Number of neutrophils 
adherent to VCAM-1, ICAM-1, MAdCAM-1 and HA after pretreatment, normalised to BSA 
control ± SEM (n=4 or 5). Statistical significance was calculated by unpaired t-test compared 
to PBS-treatment. ***P=0.002. 
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compared to that seen when endothelium and neutrophils were treated with PBS alone 
(Figure 4A). Activation of colonic endothelium alone showed the greatest increase in 
neutrophil adhesion, albeit insignificant (unactivated neutrophils/unactivated colon 
endothelium: 113.5±16.3 vs activated colon endothelium/unactivated neutrophils: 
793.4±235.36, P>0.05) while activation of both showed only a very slight increase 
(unactivated neutrophils and colon endothelium: 113.5±16.3 vs activated colon endothelium 
and neutrophils: 239.9±89.7, P>0.05).  
On comparison, around half the number of neutrophils adhered to renal endothelium than 
colon, although similar patterns in adhesion with activation were observed. Activation of renal 
endothelium alone also showed an increase in adhesion, however activation of both renal 
Figure 4 Neutrophil adherence to endothelium (A) Number of Kc-treated/untreated 
neutrophils adherent to TNF-!-treated/untreated colon endothelium (n=3). (B) Number of 
Kc-treated/untreated neutrophils adherent to TNF-!-treated/untreated renal endothelium ± 
SEM (n=4). Statistical significance was calculated by unpaired t-test compared to no 
treatment. No significant difference was detected. (C) Kc-treated neutrophil number titre to 
TNF-!-treated colon endothelium (n=1). 
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endothelium and neutrophils exhibited a decrease in adhesion (unactivated 
neutrophils/unactivated renal endothelium: 165.8±42.6 vs activated renal endothelium 
/activated neutrophils: 121.8±12.04, P>0.05). None of the observed changes in adhesion 
were statistically significant (P>0.05). To better model in vivo conditions, both neutrophils 
and endothelium were activated in the following experiments. 
A neutrophil number titre was also performed to optimise the in vitro inflammation assay. 
Between 1x105 and 1x106 Kc-treated cells were incubated with TNF-!-treated colon 
endothelium. Results showed around 0.04% of administered cells adhered to the 
endothelium with a corresponding increase observed with increasing cell number (Figure 4C). 
Subsequent experiments were performed using 5x105 cells, yielding around 200 adherent 
cells per field of view.. 
 
3.5. Neutrophil adhesion to endothelium in vitro is significantly increased by 
presence of stem cell supernatants 
The effect of pretreated MSC and HSC supernatant on inflammation was investigated by 
incubation with Kc-activated neutrophils and TNF-!-activated colon or renal endothelium, 
respectively, and observing any change in the number of adherent neutrophils. The addition 
of MSC PreTM to the in vitro inflammatory environment simultaneously with neutrophils 
significantly increased neutrophil adhesion compared to only the stimulated environment 
alone (no stem cell supernatant: 113.5±13.3 vs PreTM: 407.8±46.6, P<0.05). Illustrative 
examples of this increase are shown in figures 5A and B. Treatment with MSC TCMs 
showed no significant differences to MSC PreTM (Figure 5C). However treatment with IFN-"-, 
TNF-!-, H2O2- and Kc-HSC PostTM showed an increase in neutrophil adhesion compared to 
PreTM (Figure 5D), although only the increase mediated by H2O2-HSC PostTM treatment 
was significant (PreTM: 407.8±46.6 vs H2O2 PostTM: 675.4±76.6, P<0.05). 
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Similarly to MSC PreTM, the addition of HSC PreTM to activated renal endothelium and 
neutrophils also increased neutrophil adhesion, although this was not significant (P>0.05). 
Incubation with all HSC TCMs increased neutrophil adhesion by between 125% (PreTM: 
Figure 5 Effect of stem cell conditioned media on Kc-treated neutrophil adherence to 
TNF-!-treated endothelium (A) Representative image of neutrophils adhering to colon 
endothelium without stem cell supernatant. (B) Representative image of neutrophils 
adhering to colon endothelium in the presence of MSC-PreTM. (C-D) Number of Kc-
activated neutrophils adherent to TNF-!-treated colon endothelium in the presence of MSC 
TCM or MSC PostTM ± SEM (n=3) (E-F) Number of Kc-activated neutrophils adherent to 
TNF-!-treated renal endothelium in the presence of HSC TCM or HSC PostTM ± SEM 
(n=3). Statistical significance was calculated by unpaired t-test. PreTM was compared to Kc-
activated neutrophils alone, all other were compared to PreTM. *P<0.05. 
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233.9±47.7 vs Kc TCM: 527.33±151.99, P>0.05; Figure 5E) and 296% (PreTM: 233.9±47.7 
vs IFN-"-HSC TCM: 925.4±376.6, P>0.05; Figure 5E), however TNF-!-HSC TCM exhibited 
the only significant difference (TNF-! TCM: 790.9±164.9 vs PreTM: 233.9±47.7,  P<0.05; 
Figure 5E). All PostTMs increased adhesion, however, none of these groups reached 
significance (Figure 5F). The number of adherent neutrophils after treatment with either PBS-
HSC TCM or PBS-HSC PostTM was almost identical, as expected. Other pretreatment HSC 
PostTMs showed no major difference to these PBS-controls. 
3.6. Neutrophil adhesion to CAMs is significantly reduced by pretreatment with 
stem cell supernatants 
CAM static adhesion assays were performed with activated neutrophils pretreated with stem 
cell supernatants in order to elucidate whether the previously observed increase in neutrophil 
adhesion upon treatment was due to an affect on the endothelium or neutrophils. 
Interestingly, neutrophil pretreatment exhibited the opposite effect within the CAM static 
adhesion assay and significantly reduced neutrophil adhesion to CAMs. Incubation with PBS-, 
Kc- and H2O2-MSC TCM post activation increased adhesion of neutrophils to VCAM-1 when 
compared to Kc-activated neutrophils alone although this was not significant (Figures 6A and 
B, P>0.05). However TNF-!-MSC TCM significantly decreased neutrophil adhesion to 
VCAM-1 (Kc-activated neutrophils: 6.88±0.56 vs TNF-!-MSC TCM: 2.64±1.24, P<0.05). 
PBS- and H2O2-MSC TCM also increased neutrophil adhesion on ICAM-1 whereas SDF-1!-, 
TNF-!- and IFN-"-MSC TCM decreased the number of adherent neutrophils. None of these 
changes were statistically significant (P>0.05). MSC TCM treatments did not generally affect 
neutrophil adhesion to MAdCAM-1 and HA, although Kc-MSC TCM exhibited a non-
significant increase (Figure 6C and D).  More neutrophils adhered to MAdCAM-1 after 
treatment with Kc-MSC TCM (Figure 6C), as well as increasing neutrophil adhesion to HA 
(Figure 6D). However, both of these increases were non-significant. 
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Treatment of neutrophils with MSC PostTM yielded different results to TCM (Figure 5E-I). Figure 6 Kc-activated neu rophil CAM static adhes on assays after pretreatment with 
MSC conditioned media (A-D) Number of Kc-activated neutrophils adherent to VCAM-1, 
ICAM-1, MAdCAM-1 and HA after pretreatment with MSC TCM, normalised to BSA control ± 
SEM (n=3) (E-H) Number of Kc-activated neutrophils adherent to VCAM-1, ICAM-1, 
MAdCAM-1 and HA after pretreatment with MSC PostTM, normalised to BSA control ± SEM 
(n=3). Statistical significance was calculated by unpaired t-test compared to Kc-activated 
neutrophils alone. *P<0.05. 
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H2O2-MSC PostTM significantly decreased the number of adherent neutrophils compared to 
only Kc-activated neutrophils on VCAM-1 (Kc-activated neutrophils: 6.88±0.56 vs H2O2-MSC 
PostTM: 2.94±0.8, P<0.01; Figure 5E). All other PostTMs increased numbers of adherent 
cells, albeit non-significantly, by at between 20% (IFN-"-HSC TCM) and 504% (TNF-!-MSC 
PostTM Figure 5E). Neutrophil adhesion to ICAM-1 remained largely similar despite MSC 
PostTM treatments (Figure 5F). Similarly to VCAM-1, H2O2-MSC PostTM significantly 
decreased adherency to MAdCAM-1 (Kc-activated neutrophils: 0.80±0.15 vs H2O2-MSC 
PostTM: 0.30±0.09, P<0.05; Figure 5G). SDF-1!-, PBS- and TNF-!-MSC PostTM treatment 
all increased, non-significantly, neutrophil adhesion to MAdCAM-1 and HA whereas the other 
treatments decreased it (other than Kc-MSC PostTM to MAdCAM). 
Treatment of activated neutrophils with either HSC TCM or PostTM either decreased 
adhesion or did not affect neutrophil adhesion to VCAM-1, ICAM-1 and MAdCAM-1 (Figure 
6A-H. PBS-, H2O2- and TNF-!-HSC TCM decreased neutrophil adhesion to around that of 
BSA whereas Kc-, SDF-1!- and IFN-"-HSC TCM reduced adhesion by less of a degree 
(Figure 6A, n=1). Adhesion to ICAM-1 was decreased by between 16% (TNF-!-HSC TCM) 
and 73% (Kc-HSC TCM), although these decreases did not reach statistical significance 
(Figure 6B). PBS-HSC TCM treatment did not affect neutrophil adhesion to MAdCAM-1 
(Figure 6C) but H2O2-HSC TCM and IFN-"-HSC TCM significantly decreased neutrophil 
adhesion by 67% and 63% respectively to MAdCAM-1 (Kc-activated neutrophils: 0.80±0.15 
vs H2O2-HSC TCM: 0.26±0.03 and IFN-"-HSC TCM: 0.30±0.09, P<0.05; Figure 6C). TNF-!-
HSC TCM increased adhesion to HA, albeit this increase did not reach statistical significance 
(Figure 6D). Although all other HSC TCMs decreased adhesion, none reached statistical 
significance. 
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HSC PostTM also decreased neutrophil adhesion to VCAM-1, ICAM-1 and MAdCAM-1. Figure 7 Kc-activated neutrophil CAM static adhesion assays after pretreatment with
HSC conditioned media (A-D) Number of Kc-activated neutrophils adherent to VCAM-1, 
ICAM-1, MAdCAM-1 and HA after pretreatment with HSC TCM, normalised to BSA control ± 
SEM (n=3) (E-H) Number of Kc-activated neutrophils adherent to VCAM-1, ICAM-1, 
MAdCAM-1 and HA after pretreatment with HSC PostTM, normalised to BSA control ± SEM 
(n=3). Statistical significance was calculated by unpaired t-test compared to Kc-activated 
neutrophils alone. *P<0.05. 
 27 
Interestingly, the greatest reductions in adhesion were seen when neutrophils were treated 
with PBS-HSC PostTM, with reduced adhesion seen onICAM-1, MAdCAM-1 and HA. Kc- 
and TNF-!-HSC PostTM decreased adhesion by 45% and 53% respectively compared to 
activated-neutrophils, whereas other treatments decreased adherent neutrophil numbers by 
between 72-86%, although these decreases were not statistically significant. All decreases in 
ICAM-1 adhesion were also non-significant and ranged from H2O2-HSC PostTM (29% 
reduction) to PBS-HSC PostTM (73% reduction) (Figure 6F). PBS-HSC PostTM also 
significantly decreased neutrophil adhesion to MAdCAM-1 (Kc-activated neutrophil: 
0.80±0.15 vs PBS-HSC PostTM: 0.20±0.12, P<0.05). This was the only significant decrease 
by any PostTM treatments to any adhesion molecule. IFN-"-HSC PostTM did not affect 
neutrophil adhesion to MAdCAM-1, but all others non-significantly decreased adhesion. Kc- 
and H2O2-HSC PostTMs increased neutrophil adhesion to HA non-significantly, while other 
PostTMs decreased adhesion by one to two thirds. 
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4. Discussion 
4.1. Development and optimisation of an in vitro model to examine SC-modulated 
effects on inflammation 
In order to investigate the inflammation-modulating activity of MSC and HSC supernatants, 
an in vitro model was developed. The assay aimed to replicate in vivo inflammation by 
measuring activated, fluorescently labelled neutrophil adhesion to activated endothelium both 
with and without prior treatment with previously prepared SC supernatants.  
Neutrophils were isolated from murine BM by density centrifugation, which yielded a 
population of cells largely consisting of Gr-1-positive cells. Gr-1 expression is primarily 
limited to granulocytes (Fleming et al., 1993), the majority of which are neutrophils. This 
resulted in a pool of cells consisting primarily of neutrophils but also likely to contain small 
numbers of other cells, including eosinophils and basophils. These cells were labelled with 
CFSE for ease of analysis, and we investigated cell adhesion to VCAM-1, ICAM-1, 
MAdCAM-1 and HA. These CAMs were chosen due to their known role in the leukocyte 
adhesion cascade..  
In order to better model an in vivo environment in which neutrophils would be activated at a 
site of inflammation, static adhesion assays were performed to find the most suitable 
activator that optimally increased adhesion to CAMs. H2O2, IFN-", Kc, SDF-1! and TNF-! 
have all been previously shown to increase neutrophil adhesion to endothelium in vivo, 
however each promotes adhesion via a different mechanism, which may affect further 
experiments (Qian et al., 2011; Ellis and Beaman, 2004; Zhang et al., 2001; Petty et al., 
2009; Lauterbach et al., 2008). Kc was subsequently chosen as results found it the only 
treatment of those screened to exhibit a significant increase in neutrophil adhesion to VCAM-
1. Results were normalised to BSA due to large inter-experimental variations in the levels of 
cell adhesion. These variations may be due to the differences in the percentage of 
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neutrophils in the isolated cell populations, natural variations between animals from which 
they were isolated or possibly differences in preparation time. Increases seen with other 
treatments would may have reached statistical significance with further repeats. Kc has 
previously been shown to induce all stages in the extravasation process of neutrophil 
recruitment in vivo (Zhang et al., 2001). Other studies have also noted a small, temporary 
increase in neutrophil adhesion to endothelium after Kc treatment (Bajt et al., 2001) the data 
shown here exhibit an increase in neutrophil adhesion when treated with Kc. 
Endothelium from two tissue beds were chosen for these studies, colonic and renal, due to 
their relation to specific inflammatory disorders in vivo. IBD and nephritis are inflammatory 
conditions of the colon and kidney, respectively, which are affecting many in the Western 
world. TNF-! was chosen to activate these endothelial cells due to its successful use as an 
endothelial activator for a long period of time in neutrophil adhesion experiments (Meekins et 
al., 1994; Ishii et al., 1994). Indeed, in this study, activation of the endothelium with TNF-! 
increased neutrophil adhesion to endothelium. While both TNF-!-treated endothelium and 
Kc-treated neutrophils displayed an increase in neutrophil adhesion to endothelium, 
interestingly, when treatments were combined adhesion was less than seen for each 
treatment individually. This is unexpected as TNF-! treatment is known to increase ICAM-1 
and VCAM-1 surface expression on endothelium and we have shown here that Kc-activation 
of neutrophils increases VCAM-1 adhesion (Mackay et al., 1994). 
Three sets of conditioned SC media were generated: PreTM, TCM and PostTM. PreTM 
contained only constitutive secretions to examine effects of unstimulated SCs whereas TCM 
and PostTM were produced to examine the effects of cytokine, chemokine and ROS 
treatment on secretion. Relative concentrations of treatments were chosen in line with 
previous work (Kavanagh et al., 2013;White et al., in press, 2013). TCM was obtained 
immediately following treatment so contained the stimulated secreted agents but also 
contained the original stimulant. Although the presence of the additional stimulant may 
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disguise any anti-inflammatory effects, it would be likely to contain the highest concentration 
of secretions. PostTM, while not containing of the original treatment agent, may contain a 
lower concentration of secretions, or none at all. As these supernatants were collected in 
succession, TCM and PostTM were also produced by a higher number of cells due to 
proliferation over the 48- and 72-hour period, respectively, which may also affect the 
comparability of the two supernatants.  
4.2. MSC and HSC conditioned media exhibit pro-inflammatory effects in vitro 
The developed inflammation assay was then used to assay the inflammatory-modulating 
capability of untreated SC supernatant. Work within the lab has previously shown positive 
effects of HSC transfer on renal inflammation and previous studies have shown MSC-colon 
benefits, therefore these conditions were modelled in this thesis (Van Deen et al., 2013). 
Incubation with untreated MSC conditioned media (PreTM) exhibited a significant increase in 
neutrophil adhesion to colon endothelium, increasing neutrophil adhesion by 70%. Although 
non-significant, a similar effect was produced by HSC PreTM on renal endothelium (90% 
increase). These results suggest that both SCs constitutively secrete pro-inflammatory 
agents. MSCs have previously been shown to secrete large amounts of the pro-inflammatory 
cytokines IL-6 and IL-8 as well as the chemokine CCL2 (Hoogduijn et al., 2010). IL-6 and IL-
8 are known to increase lymphocyte adhesion to endothelium by upregulation of adhesion 
molecules (Watson et al., 1996; Barnes et al., 2011; Arndt et al., 1996; Gerszten et al., 1999) 
whereas CCL2 is thought to mediate neutrophil firm adhesion (Reichel et al., 2009). MSCs 
are also known to basally secrete transforming growth factor-#1 (TGF-#1)  (Di Nicola et al., 
2002), a cytokine that is thought to be anti-inflammatory. TGF-#1 has been shown to 
decrease neutrophil adhesion to endothelium by inhibiting E-selectin and VCAM-1 
expression (Gamble et al., 1993; Park et al., 2000). In the current study, the effect of pro-
inflammatory agents must predominate that of anti-inflammatory agents. 
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The neutrophils used for these experiments were applied to the endothelium in the Kc-
containing media used to activate them. Kc does not affect endothelial cells directly (Zhang 
et al., 2001), however the increased activation period is likely to increase neutrophil 
stimulation. However, all treatments were carried out in a similar manner; therefore any 
exhibited effects were consistent. 
4.3. MSC and HSC pretreatment with inflammatory cytokines increases the pro-
inflammatory effect of conditioned media 
The effect of pretreatment of SCs with cytokines and chemokines on inflammation-
modulating activity was then investigated using the in vitro inflammation model. Interestingly, 
none of the MSC TCMs had any major effect on inflammation compared to PreTM despite 
containing the original  activatory agents. However, PostTMs (other than PBS- and SDF-1!), 
which should not contain any of the original activating factors, exhibited a marked increase in 
cell recruitment. The most likely reason for this is that after 48 hours of treatment, the MSCs 
secrete pro-inflammatory agents at a higher rate, leading to higher concentrations in the 
conditioned media. H2O2-MSC PostTM exhibited the only significant increase in inflammation 
compared to PreTM (66% increase in neutrophil adhesion). TNF-! treatment of Wharton’s 
Jelly MSCs has previously been shown to increase IL-6 expression by 25 times, which as 
previously mentioned increases CAM expression (Prasanna et al., 2010). The results from 
our inflammation model also show a non-significant increase in neutrophil recruitment upon 
IFN-"-MSC PostTM treatment. IFN-"-treated MSCs have previously been shown to increase 
the secretion of pro-inflammatory agents, such as soluble ICAM-1, CXCL10 and CCL8 
(Hoogduijn et al., 2010).  
Both HSC TCMs and PostTMs increased inflammation compared to PreTM, although these 
were mostly non-significant. Even PBS-treated HSCs exhibited a marked increase, which 
may be due to an increase in HSCs secreting the conditioned media. However this effect 
was not also seen between TCM and PostTM results. TNF-!-HSC TCM showed the only 
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significant increase in inflammation compared to PreTM exhibiting a 232% increase in 
neutrophil adhesion. Studies have identified roles for TNF-! in HSC regulation and 
maintenance, but no previous work has investigated the capacity for HSCs to modulate 
inflammation following such treatment (Pronk et al., 2011; Rebel et al., 1999).  
4.4. Media conditioned by stimulated MSCs or HSCs exhibits anti-inflammatory 
effects on neutrophils in vitro 
Static adhesion assays were performed on activated neutrophils pretreated with 
inflammatory cytokines and chemokines in order to elucidate whether the previously 
observed effects exerted by SC conditioned media were on endothelium or neutrophils. 
Interestingly, the results were largely different to the in vitro inflammation assay. 
MSC TCM and PostTM exhibited differing effects on neutrophil adhesion  (except for PBS 
treatment, which remained - as expected - largely the same). H2O2- and Kc-MSC TCM 
generally increased adhesion, whereas their relative PostTMs were anti-inflammatory. 
Indeed, the anti-inflammatory effects of H2O2-MSC PostTM on VCAM-1 and MAdCAM-1 
were the only effects to reach statistical significance. The pro-inflammatory effect of the 
TCMs may be expected as they contain the original treatment factor. Both Kc and H2O2 were 
both previously shown to increase neutrophil adhesion to CAMs therefore their pro-
inflammatory effects predominate over any anti-inflammatory effects. The opposite 
relationship between TCM and PostTM was observed for SDF-1! and TNF-!: the TCMs 
showed either no change or reduced neutrophil adhesion, while PostTMs showed no change 
or were enhanced neutrophil adhesion. Both SDF-1!- and TNF-!-treatment of neutrophils 
exhibited the lowest increase in adhesion; therefore any anti-inflammatory agents within the 
TCM predominated. These agents may be at the highest level in TCM and were either 
depleted in PostTMs, or HSCs may have subsequently secreted pro-inflammatory agents 
after stimulation was removed. 
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The potent immunosuppressive capacity of MSC secretions has been well documented but 
most of actions are exerted on T-cells by agents such as hepatocyte growth factor, nitric 
oxide and HLA-G (Hoogduijn et al., 2010). However, one study in particular has shown that, 
when grown in co-culture with PHA-activated lymphocytes, MSCs decreased lymphocyte 
production of TNF-!, IFN-" and IL-2 (Prasanna et al., 2010). Pretreatment of MSCs with pro-
inflammatory cytokines such as IFN-" has also been shown to decrease inflammation in an 
allogenic mixed lymphocyte response model (Ryan et al., 2007).  
All conditioned media from treated HSCs exerted an anti-inflammatory effect on neutrophils, 
decreasing or not affecting adhesion to VCAM-1, ICAM-1 and MAdCAM-1 compared to 
none-treated. Even PBS-treatment, and therefore basal HSC secretions, markedly 
decreased neutrophil adhesion. The decrease exerted by PBS-HSC PostTM on MAdCAM-1 
reached statistical significance, which could indicate that a large number of cells are required 
in order for effective concentrations of anti-inflammatory agents to accumulate, although 
without knowing the number of cells present it is not possible to know for sure. Interestingly, 
the anti-inflammatory effect predominated any pro-inflammatory effects of the treatments 
within the TCM. The importance of the decrease in adhesion to VCAM-1 is unclear, as the 
experiment requires additional replicates for statistical strength. H2O2-HSC TCM, despite 
containing the potently pro-inflammatory H2O2, and IFN-"-HSC TCM showed the only 
significant decreases in neutrophil adhesion (to MAdCAM-1). H2O2-treatment of HSCs has 
been shown to increase their adhesion within the gut, while not affecting their proliferative 
ability or viability (Kavanagh et al., 2012). IFN-" is known to interact with HSCs and stimulate 
their activation and proliferation (Zhao et al., 2010; Baldridge et al., 2010). However, the 
effect on inflammation has not previously been investigated. 
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4.5. Future work 
The body of literature covering the inflammation-mediating activity of stem cells is 
accumulating; much work is needed in order for a comprehensive understanding of their 
functioning. As such, the work within this thesis could be expanded further in several ways.  
Previous investigations into the inflammatory-mediating activity of SCs have been conducted 
using coculture with endothelium (Prasanna et al., 2010). This method not only eliminates 
any problems that may occur with freeze-thawing of supernatants, but is more relevant to in 
vivo applications. This method also could be used to investigate contact-dependent 
inflammation-mediating activity, whereas transwell coculture would allow investigation of the 
activity of secreted factors. The use of T-cell proliferation assays would also allow further 
insight into the more expansive view on inflammation-mediating activity. 
These techniques could be further used for the optimisation of SC conditioned media to 
discover the optimal activation periods, treatment concentrations, possible combinations of 
treatments and combinations of SCs on specific endothelial types that produce the greatest 
immunomodulatory effects. This would be of great interest within the clinic as a therapeutic 
for inflammatory disorders. 
The mechanism of action within this thesis has been purely speculative based on previous 
work, however the conditioned media could be analysed via Enzyme-linked immunosorbent 
assays (ELISA). The conditioned media could be screened for the presence of pro- and anti-
inflammatory mediators that have been previously suggested, for example interleukins such 
as IL-6 and IL-8, chemokine (C-C motif) ligands such as CCL2 and CCL8, TGF#1 and 
soluble CAMs. These experiments would provide mechanistic details as to how conditioned 
media may function, and the changes in supernatant composition induced by the treatments. 
The effect of SC conditioned media could also be observed in vivo via intravital microscopy. 
The change in the number of adherent cells to inflamed organs can be monitored in this way 
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in real time. Treated SCs can also be administered as well as labelling internal neutrophils in 
order to assess in vivo changes in inflammation 
4.6. Concluding remarks 
SC therapy for inflammation is very much in its infancy and holds much promise for the future 
(Otto and Wright, 2011). SCs are already appearing within the clinic, however, fundamental 
knowledge of their effects on inflammation and the mechanisms of action have lead to 
criticisms their use is premature (Leone and Crea, 2006). This thesis aimed to better 
understand the inflammation-mediating activities of both MSCs and HSCs by in vitro 
methods. It is reported here that SC conditioned media has multiple effects on inflammation. 
Further, SCs in an inflammatory environment were shown to enhance the inflammation-
mediating effect of the conditioned media they produced. This study not only gives a greater 
understanding of SC activity, but the data within could be used to inform studies for use in 
the clinic.  
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